WO2021151265A1 - 一种醛基类化合物的药物用途 - Google Patents

一种醛基类化合物的药物用途 Download PDF

Info

Publication number
WO2021151265A1
WO2021151265A1 PCT/CN2020/081481 CN2020081481W WO2021151265A1 WO 2021151265 A1 WO2021151265 A1 WO 2021151265A1 CN 2020081481 W CN2020081481 W CN 2020081481W WO 2021151265 A1 WO2021151265 A1 WO 2021151265A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
branched
group
substituents
straight
Prior art date
Application number
PCT/CN2020/081481
Other languages
English (en)
French (fr)
Inventor
柳红
李建
戴文豪
彭晶晶
谢雄
胡树雷
李淳朴
许叶春
杨海涛
张磊砢
苏海霞
蒋华良
靳振明
肖庚富
陈凯先
Original Assignee
中国科学院上海药物研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中国科学院上海药物研究所 filed Critical 中国科学院上海药物研究所
Priority to CN202080095393.2A priority Critical patent/CN115087653B/zh
Priority to EP20916984.6A priority patent/EP4098653A1/en
Priority to US17/759,807 priority patent/US20230138310A1/en
Publication of WO2021151265A1 publication Critical patent/WO2021151265A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the invention relates to the field of medicine, in particular to the medical use of an aldehyde-based compound.
  • 2019-nCoV coronavirus
  • SARS-CoV-2 coronavirus
  • the 2019-nCoV coronavirus belongs to the genus Coronavirus of the Coronavirus family, and is a single-stranded positive-sense RNA virus with an envelope. Similar to other known coronaviruses, the 2019-nCoV coronavirus also completes the proliferation of progeny viruses through several processes such as adsorption, penetration, uncoating, biosynthesis, and assembly and release of progeny viruses.
  • the infection of host cells by the 2019-nCoV coronavirus starts when the spike glycoprotein on the surface of the virus envelope binds to the receptor on the surface of the host cell, and then membrane fusion occurs. The virus enters the host cell and is released under the action of cell lysosomes and other organelles.
  • the single-stranded sense RNA of the virus’s genetic material is translated to produce polyproteins under the action of the host cell’s mitochondria, ribosomes and other protein synthesis elements and necessary raw materials.
  • the two essential cysteamines of the 2019-nCoV coronavirus Acid protease Papain-like protease (PL pro ) and 3C-like protease (3C-like protease, 3CL pro ) cleave and process polyprotein precursors at specific sites, producing multiple important factors for the virus life cycle Non-structural protein.
  • the viral RNA replicates the nucleic acid material of the progeny virus, and a large number of required structural proteins are translated to complete the assembly and release of the progeny virus.
  • Any link or key enzyme in the life cycle of cells infected by the 2019-nCoV coronavirus can be used as research targets for antiviral drugs, such as the cysteine proteases PL pro and 3CL pro that hydrolyze and cleave polyprotein precursors, which are responsible for the completion of the product.
  • 3CL protease (3 chymotrypsin-like protease, 3CL pro ), also known as the main protease (M pro ), is the key protease in the process of producing multiple non-structural proteins after the coronavirus RNA is translated into polyproteins pp1a and pp1ab. Inhibition of the catalytic function of 3CL protease can effectively inhibit the cleavage of viral polyprotein precursors, block viral replication and inhibit the generation of progeny viruses.
  • 3CL pro is a cysteine protease, which is a key protease that catalyzes the proteolysis of single positive-strand RNA virus precursors, and plays an important role in the replication activity of coronaviruses such as 2019-nCoV. Therefore, 3CL pro is currently recognized as an ideal target for the development of anti-coronavirus drugs.
  • the purpose of the present invention is to provide a new use of aldehyde-based compounds.
  • the present invention provides an aldehyde compound represented by the general formula I as a 2019 new coronavirus (2019-nCov) 3CL protease inhibitor in the preparation of treatment and/or prevention and alleviation of respiratory tract infection caused by 2019 new coronavirus infection. , Pneumonia and other related diseases.
  • an aldehyde compound represented by general formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer or racemate thereof The purpose of which is characterized in that it is used to prepare (a) 2019 new coronavirus (2019-nCov) 3CL protease inhibitor; and (b) treat and/or prevent and alleviate infection caused by 2019 new coronavirus (2019-nCov) Drugs for related diseases:
  • the chiral carbon atoms C*, C* 2 , C* 3 , and C* 4 are each independently S-type, R-type, or a combination thereof;
  • n 0 or 1;
  • R 1 is selected from the following groups which are unsubstituted or substituted by 1-3 substituents: C3-C7 cycloalkyl, trifluoromethyl, C2-C6 alkynyl, 4--7 membered heterocyclic group, C5-C7 Aryl group, 5- to 7-membered heteroaryl group; the heterocyclic group and heteroaryl group each contain 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen; the substituents are each independently selected from the following group: Halogen, C1 ⁇ C4 straight or branched chain alkyl, C1 ⁇ C4 straight or branched alkenyl, C2 ⁇ C4 straight or branched alkynyl, C1 ⁇ C4 straight or branched alkoxy, C1 ⁇ C4 Straight or branched chain alkylcarbonyloxy, cyano, nitro, hydroxyl, amino, hydroxymethyl, trifluoromethyl, carboxyl, mercapto, C1-C4 acyl, amide, sulf
  • R 2 is selected from the following groups that are unsubstituted or substituted by 1-3 substituents: C3 to C7 cycloalkyl, 5 to 12 membered heterocyclic group (preferably 5 to 7 membered heterocyclic group or 6 membered aryl group And 5- 7-membered heterocyclic group), C6-C12 aryl, 5-12-membered heteroaryl, styryl, or -Cbz; wherein each of the heterocyclic groups or heteroaryl groups contains 1 to 3 selected Heteroatoms from oxygen, sulfur and nitrogen; the substituents are each independently selected from halogen, C1-C6 linear or branched alkyl, C2-C6 linear or branched alkenyl, C2-C6 linear or Branched alkynyl, C1 ⁇ C6 linear or branched alkoxy, C1 ⁇ C6 linear or branched alkylcarbonyloxy, cyano, nitro, hydroxyl, amino, hydroxymethyl, trifluoromethyl
  • R 3 is selected from the following groups which are unsubstituted or substituted by 1-3 substituents: C1 ⁇ C6 linear or branched alkyl, C1 ⁇ C6 linear or branched alkoxy, C3 ⁇ C7 cycloalkyl , C6-C12 aryl, 5--12 membered heteroaryl, wherein the heteroaryl contains 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen; wherein, the substituents are each independently selected from halogen , C1 ⁇ C6 straight or branched chain alkyl, C2 ⁇ C6 straight or branched alkenyl, C2 ⁇ C6 straight or branched alkynyl, C1 ⁇ C6 straight or branched alkoxy, C1 ⁇ C6 straight Chain or branched alkylcarbonyloxy, cyano, nitro, hydroxyl, amino, hydroxymethyl, trifluoromethyl, carboxyl, mercapto, C1-C4 acyl, amide, sulfonyl,
  • the related disease caused by the 2019 novel coronavirus infection is selected from the following group: respiratory tract infection, pneumonia and its complications, or a combination thereof.
  • R 1 is selected from the following groups that are unsubstituted or substituted by 1-3 substituents: trifluoromethyl, alkynyl, cyclopropyl, cyclobutanyl, cyclopentyl, Cyclohexyl, phenyl, thienyl, pyrazolyl, thiazolyl, pyridyl, furyl.
  • R 1 is selected from the following groups that are unsubstituted or substituted by 1-3 substituents: trifluoromethyl, alkynyl, cyclopropyl, cyclobutanyl, cyclopentyl, Cyclohexyl, phenyl, thienyl, pyrazolyl, thiazolyl, pyridyl, furyl; and/or
  • R 2 is a group selected from the group consisting of unsubstituted or substituted by 1-3 substituents: phenyl, styryl, benzoheterocyclyl, 5-12 membered heteroaryl; preferably, the Benzo heterocycles and 5-12 membered heteroaromatic rings are selected from benzodioxole, indole, isoxazole, 2-hydroproppyran, pyridine, pyrazole, dihydroimidazopyridine, imidazo Pyridine, benzothiophene, dihydrobenzodioxane, quinoxaline, benzofuran, indazole, benzimidazole, quinoline.
  • one or more of the chiral carbon atoms C*, C* 2 , C* 3 , and C* 4 are S-type.
  • the chiral carbon atoms C*, C* 2 , C* 3 , and C* 4 are S-type; and/or
  • R 1 is selected from the following groups that are unsubstituted or substituted by 1-3 substituents: trifluoromethyl, alkynyl, cyclopropanyl, cyclobutanyl, cyclopentyl, cyclohexyl, phenyl , Thienyl, pyrazolyl, thiazolyl, pyridyl, furyl; and/or
  • R 2 is a group selected from the group consisting of unsubstituted or substituted by 1-3 substituents: phenyl, styryl, benzoheterocyclyl, 5-12 membered heteroaryl; preferably, the Benzo heterocycles and 5-12 membered heteroaromatic rings are selected from benzodioxole, indole, isoxazole, 2-hydroproppyran, pyridine, pyrazole, dihydroimidazopyridine, imidazo Pyridine, benzothiophene, dihydrobenzodioxane, quinoxaline, benzofuran, indazole, benzimidazole, quinoline; and/or
  • R 3 is selected from the following groups that are unsubstituted or substituted by 1-3 substituents: C1-C6 linear or branched alkyl, C3-C7 cycloalkyl, phenyl.
  • the compound in the general formula (I) is selected from the following group:
  • a pharmaceutical composition which comprises (a) a therapeutically effective amount of an aldehyde compound represented by general formula (I), or a pharmaceutically acceptable salt or enantiomer thereof Isomers, diastereomers or racemates or prodrugs, and (b) a pharmaceutically acceptable carrier, wherein the aldehyde-based compound represented by the general formula (I) is as described in the first aspect of the present invention Narrated.
  • the use of the pharmaceutical composition according to the second aspect of the present invention is provided, which is used for preparing treatment and/or prevention and alleviation of related diseases caused by 2019 novel coronavirus (2019-nCov) infection. drug.
  • the related disease caused by the 2019 novel coronavirus infection is selected from the following group: respiratory tract infection, pneumonia and its complications, or a combination thereof.
  • the chiral carbon atoms C*, C* 2 , C* 3 , and C* 4 are each independently S-type, R-type, or a combination thereof;
  • n 0 or 1;
  • R 1 is selected from the following groups which are unsubstituted or substituted by 1-3 substituents: C3-C7 cycloalkyl, trifluoromethyl, C2-C6 alkynyl, 4--7 membered heterocyclic group, C5-C7 Aryl group, 5- to 7-membered heteroaryl group; the heterocyclic group and heteroaryl group each contain 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen; the substituents are each independently selected from the following group: Halogen, C1 ⁇ C4 straight or branched chain alkyl, C1 ⁇ C4 straight or branched alkenyl, C2 ⁇ C4 straight or branched alkynyl, C1 ⁇ C4 straight or branched alkoxy, C1 ⁇ C4 Straight or branched chain alkylcarbonyloxy, cyano, nitro, hydroxyl, amino, hydroxymethyl, trifluoromethyl, carboxyl, mercapto, C1-C4 acyl, amide, sulf
  • R 2 is selected from the following groups that are unsubstituted or substituted by 1-3 substituents: C3 to C7 cycloalkyl, 5 to 12 membered heterocyclic group (preferably 5 to 7 membered heterocyclic group or 6 membered aryl group And 5- 7-membered heterocyclic group), C6-C12 aryl, 5--12-membered heteroaryl, styryl, or -Cbz; wherein each of the heterocyclic group or heteroaryl contains 1 to 3 selected Heteroatoms from oxygen, sulfur and nitrogen; the substituents are each independently selected from halogen, C1-C6 linear or branched alkyl, C2-C6 linear or branched alkenyl, C2-C6 linear or Branched alkynyl, C1 ⁇ C6 linear or branched alkoxy, C1 ⁇ C6 linear or branched alkylcarbonyloxy, cyano, nitro, hydroxyl, amino, hydroxymethyl, trifluoromethyl,
  • R 3 is selected from the following groups which are unsubstituted or substituted by 1-3 substituents: C1 ⁇ C6 linear or branched alkyl, C1 ⁇ C6 linear or branched alkoxy, C3 ⁇ C7 cycloalkyl , C6-C12 aryl, 5--12 membered heteroaryl, wherein the heteroaryl contains 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen; wherein, the substituents are each independently selected from halogen , C1 ⁇ C6 straight or branched chain alkyl, C2 ⁇ C6 straight or branched alkenyl, C2 ⁇ C6 straight or branched alkynyl, C1 ⁇ C6 straight or branched alkoxy, C1 ⁇ C6 straight Chain or branched alkylcarbonyloxy, cyano, nitro, hydroxyl, amino, hydroxymethyl, trifluoromethyl, carboxyl, mercapto, C1-C4 acyl, amide, sulfonyl,
  • R 1 is selected from the following groups that are unsubstituted or substituted by 1-3 substituents: trifluoromethyl, alkynyl, cyclopropyl, cyclobutanyl, cyclopentyl, Cyclohexyl, phenyl, thienyl, pyrazolyl, thiazolyl, pyridyl, furyl.
  • R 1 is selected from the following groups that are unsubstituted or substituted by 1-3 substituents: trifluoromethyl, alkynyl, cyclopropyl, cyclobutanyl, cyclopentyl, Cyclohexyl, phenyl, thienyl, pyrazolyl, thiazolyl, pyridyl, furyl; and/or
  • R 2 is a group selected from the group consisting of unsubstituted or substituted by 1-3 substituents: phenyl, styryl, benzoheterocyclyl, 5-12 membered heteroaryl; preferably, the Benzo heterocycles and 5-12 membered heteroaromatic rings are selected from benzodioxole, indole, isoxazole, 2-hydroproppyran, pyridine, pyrazole, dihydroimidazopyridine, imidazo Pyridine, benzothiophene, dihydrobenzodioxane, quinoxaline, benzofuran, indazole, benzimidazole, quinoline.
  • the chiral carbon atoms C*, C* 2 , C* 3 , and C* 4 are S-type; and/or
  • R 1 is selected from the following groups that are unsubstituted or substituted by 1-3 substituents: trifluoromethyl, alkynyl, cyclopropanyl, cyclobutanyl, cyclopentyl, cyclohexyl, phenyl , Thienyl, pyrazolyl, thiazolyl, pyridyl, furyl; and/or
  • R 2 is a group selected from the group consisting of unsubstituted or substituted by 1-3 substituents: phenyl, styryl, benzoheterocyclyl, 5-12 membered heteroaryl; preferably, the Benzo heterocycles and 5-12 membered heteroaromatic rings are selected from benzodioxole, indole, isoxazole, 2-hydroproppyran, pyridine, pyrazole, dihydroimidazopyridine, imidazo Pyridine, benzothiophene, dihydrobenzodioxane, quinoxaline, benzofuran, indazole, benzimidazole, quinoline; and/or
  • R 3 is selected from the following groups that are unsubstituted or substituted by 1-3 substituents: C1-C6 linear or branched alkyl, C3-C7 cycloalkyl, phenyl.
  • the compounds in the general formula (I) are compounds 1 to 88 in Table A.
  • a method for treating, preventing, and/or alleviating related diseases caused by 2019 novel coronavirus (2019-nCov) infection including the steps of: administering a safe and effective amount of The aldehyde-based compound represented by the general formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer, or racemate thereof, wherein the general formula (I) is The aldehyde-based compounds shown are as described above.
  • the subject is a primate mammal, such as a human.
  • a method for inhibiting the activity of the 3CL protease of the 2019 novel coronavirus which comprises the steps of: combining the aldehyde compound represented by the general formula (I), or the pharmacological agent thereof The above acceptable salts, enantiomers, diastereomers or racemates are contacted with the 3CL protease of 2019-nCov, thereby inhibiting the activity of the 3CL protease of 2019-nCov.
  • the method is non-therapeutic and non-diagnostic.
  • the method is in vitro.
  • the 3CL protease of 2019-nCov is a recombinant or expressed 3CL protease of 2019-nCov.
  • Figure 1 shows that the compounds of the present invention can inhibit the replication of 2019nCoV virus.
  • Figure 2 shows the inhibition curve and EC50 value of some compounds of the present invention in inhibiting the 2019 novel coronavirus (2019-nCov).
  • Figure 3 shows the structure of the crystal complex formed by compounds 48 and 81 and SARS-CoV-2 3Cl pro.
  • the inventors unexpectedly developed for the first time a class of active ingredients that can effectively inhibit the 2019 novel coronavirus (2019-nCov), that is, the compound represented by general formula I or its pharmacologically Acceptable salts, enantiomers, diastereomers or racemates.
  • 2019-nCov the compound represented by general formula I or its pharmacologically Acceptable salts, enantiomers, diastereomers or racemates.
  • Tests have shown that the active ingredients of the present invention can effectively inhibit the activity of the 3CL protease of the 2019 novel coronavirus (2019-nCov), thereby inhibiting the replication and viability of 2019-nCov.
  • the present invention has been completed on this basis.
  • substituted refers to the substitution of one or more hydrogen atoms on the group with a substituent selected from the following group: C 1 ⁇ C 10 alkyl, C 3 ⁇ C 10 cycloalkane Group, C 1 ⁇ C 10 alkoxy, halogen, hydroxyl, carboxyl (-COOH), C 1 ⁇ C 10 aldehyde group, C 2 ⁇ C 10 acyl group, C 2 ⁇ C 10 ester group, amino, phenyl;
  • the phenyl group includes an unsubstituted phenyl group or a substituted phenyl group having 1 to 3 substituents, and the substituents are selected from the group consisting of halogen, C 1 -C 10 alkyl, cyano, OH, nitro, C 3 -C 10 cycloalkyl, C 1 -C 10 alkoxy, amino.
  • each chiral carbon atom may optionally be in the R configuration or the S configuration, or a mixture of the R configuration and the S configuration.
  • C1-C6 alkyl group refers to a straight or branched chain alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, Tert-butyl, or similar group.
  • 3-8 membered heterocyclic group refers to a group formed by losing one hydrogen atom of a 3-8 membered saturated ring with 1-3 heteroatoms selected from the group: N, S, O; for example, pyrrolidinyl, Piperidinyl, piperazinyl, morpholinyl, or similar groups.
  • 6-10 membered aryl group refers to a group formed by losing one hydrogen atom of a 6-10 membered aryl group; for example, a phenyl group, a naphthyl group, or the like.
  • 5- to 10-membered heteroaryl refers to a 5- to 8-membered aryl group with 1-3 heteroatoms selected from the group consisting of N, S, O, each of which is formed by losing one hydrogen atom.
  • the ring system of the group can be monocyclic or polycyclic; for example, pyrrolyl, pyridyl, thienyl, furyl, imidazolyl, pyrimidinyl, benzothienyl, indolyl, imidazopyridyl, quinolinyl Or similar groups.
  • C1 ⁇ C6 alkoxy refers to a straight or branched alkoxy group having 1-6 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso Butoxy, sec-butoxy, tert-butoxy, or similar groups.
  • C2-C6 alkenyl refers to a group formed by the loss of one or two hydrogen atoms of an olefin with 2-6 carbon atoms.
  • halogen refers to F, Cl, Br, and I.
  • the structural formula described in the present invention is intended to include all isomeric forms (such as enantiomers, diastereomers and geometric isomers (or conformational isomers): for example, containing asymmetric centers
  • the R and S configurations, the (Z), (E) isomers and the (Z), (E) conformational isomers of the double bond Therefore, the single stereochemical isomers of the compounds of the present invention or their enantiomers Mixtures of isomers, diastereomers or geometric isomers (or conformational isomers) all fall within the scope of the present invention.
  • tautomers means that structural isomers with different energies can exceed the low energy barrier and thus convert into each other.
  • proton tautomers ie, proton transfer
  • interconversion through proton transfer such as 1H-indazole and 2H-indazole, 1H-benzo[d]imidazole and 3H-benzo[d]imidazole
  • Valence tautomers include interconversion through some bond-forming electron recombination.
  • C1 ⁇ C6 means that the group can have 1 to 6 carbon atoms, for example, 1, 2, 3, 4, or 5.
  • an active ingredient that can effectively inhibit the replication of the 2019 novel coronavirus (2019-nCov) is provided.
  • the active ingredient is a compound represented by general formula I, and the active ingredient can effectively prevent, treat and/or alleviate 2019-nCov related diseases.
  • the active ingredient of the present invention includes the aldehyde compound represented by the general formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer or racemate, or Its prodrug. It should be understood that the active ingredient of the present invention also includes the crystalline form, amorphous compound, and deuterated compound of the compound of general formula (I).
  • the "pharmaceutically acceptable salt” refers to the reaction of a compound of general formula (I) with an inorganic acid or an organic acid to form a conventional non-toxic salt.
  • a conventional non-toxic salt can be prepared by reacting a compound of general formula (I) with an inorganic acid or organic acid.
  • the inorganic acid includes hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, aminosulfonic acid and phosphoric acid, etc.
  • Organic acids include citric acid, tartaric acid, lactic acid, pyruvic acid, acetic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, naphthalenesulfonic acid, ethanesulfonic acid, naphthalene disulfonic acid, maleic acid, malic acid, malonic acid Acid, fumaric acid, succinic acid, propionic acid, oxalic acid, trifluoroacetic acid, stearic acid, pamoic acid, hydroxymaleic acid, phenylacetic acid, benzoic acid, salicylic acid, glutamic acid, ascorbic acid, p-aminobenzene Sulfonic acid, 2-acetoxybenzoic acid and isethionic acid, etc.; or compounds of general formula (I) and propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid,
  • the present invention also provides aldehyde-based compounds represented by general formula (I), or pharmaceutically acceptable salts, enantiomers, diastereomers or racemates and prodrugs thereof
  • aldehyde-based compounds represented by general formula (I) or pharmaceutically acceptable salts, enantiomers, diastereomers or racemates and prodrugs thereof
  • One or more mixtures are the use of active ingredients in the preparation of medicines for the treatment and/or prevention and alleviation of respiratory tract infections, pneumonia and other related diseases caused by 2019 novel coronavirus infection.
  • the pharmaceutical composition provided by the present invention preferably contains the active ingredient in a weight ratio of 0.001-99wt%, the preferred ratio is that the compound of general formula I as the active ingredient accounts for 0.1wt% to 90wt% of the total weight, and the rest is pharmaceutically acceptable.
  • the carrier includes conventional diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption promoters, surfactants, adsorption carriers, lubricants and the like in the pharmaceutical field.
  • the compounds and pharmaceutical compositions provided by the present invention can be in various forms, such as tablets, capsules, powders, syrups, solutions, suspensions and aerosols, etc., and can be present in suitable solid or liquid carriers or diluents. Neutralization is suitable for sterilization equipment for injection or drip infusion.
  • the unit measurement of the preparation formula usually contains 0.05-400 mg of the compound of the general formula I, preferably, the unit measurement of the preparation formula contains 1 mg-500 mg of the compound of the general formula I.
  • the compounds and pharmaceutical compositions of the present invention can be used clinically on mammals, including humans and animals, and can be administered via oral, nose, skin, lung, or gastrointestinal tract. Most preferred is oral administration.
  • the most preferred daily dose is 0.01-400 mg/kg body weight, taken in one time, or 0.01-200 mg/kg body weight in divided doses. Regardless of the method of administration, the individual's optimal dosage should be determined based on the specific treatment. Usually, start with a small dose and gradually increase the dose until the most suitable dose is found.
  • the drugs or inhibitors of the present invention can be administered in various ways, for example, can be introduced into the body by injection, spraying, nose drops, eye drops, penetration, absorption, physical or chemically mediated methods such as muscle, intradermal, subcutaneous, and intravenous methods. , Mucosal tissue; or mixed or wrapped by other substances into the body.
  • the compound of the present invention can effectively inhibit 2019-nCoV 3CL protease, and the IC50 value of some compounds reaches about 70 nM.
  • the compound of the present invention has low toxic and side effects and good drug-making properties.
  • the analytical data of the sample was measured by the following instruments: NMR was measured by GEMINI-300, Bruker AMX-400 and INVOA-600 nuclear magnetic resonance instruments, TMS (tetramethylsilane) was internal standard, chemical shift unit was ppm, coupling The constant unit is Hz; the mass spectrum is measured by Finnigan MAT-711, MAT-95 and LCQ-DECA mass spectrometers and IonSpec 4.7 Tesla mass spectrometers.
  • N-tert-butoxycarbonyl-L-glutamate dimethyl 1-1 (6g, 21.8mmol) in 60mL of anhydrous tetrahydrofuran, and slowly drop LiHMDS(1M in THF) in tetrahydrofuran solution (47 mL, 47 mmol), the temperature was kept stable at -78°C during the dropping process for about 1 hour. After dripping, it was stirred at -78°C for 1 hour. Bromoacetonitrile (2.79 g, 23.3 mmol) was dissolved in 20 ml of tetrahydrofuran, and then the solution was slowly dropped into the reaction system, and the dropping process lasted 1 to 2 hours.
  • Example 1 The acid 1-11 in Example 1 is replaced with compound 2-1, and the synthesis method refers to the synthesis of compound 1 to obtain compound 2.
  • Example 1 Replace acid 1-11 in Example 1 with compound 2-1, and replace 1-5 in Example 1 with compound 3-1.
  • the synthesis method refers to the synthesis of compound 1, and compound 3 is obtained.
  • Example 1 The acid 1-11 in Example 1 is replaced with compound 5-1, and the synthesis method refers to the synthesis of compound 1, to obtain compound 5.
  • Compound 6-1 is used to replace acid 1-11 in Example 1, and the synthesis method refers to the synthesis of compound 1, to obtain compound 6.
  • Example 1 Replace acid 1-11 in Example 1 with compound 6-1, and replace 1-5 in Example 1 with compound 8-1.
  • the synthesis method refers to the synthesis of compound 1, to obtain compound 8.
  • Example 1 Replace acid 1-11 in Example 1 with compound 10-1, and replace 1-5 in Example 1 with compound 8-1.
  • the synthesis method refers to the synthesis of compound 1, to obtain compound 10.
  • Example 1 Replace acid 1-11 in Example 1 with compound 11-1, and replace 1-5 in Example 1 with compound 8-1.
  • the synthesis method refers to the synthesis of compound 1, to obtain compound 11.
  • Example 1 Replace acid 1-11 in Example 1 with compound 5-1, and replace 1-5 in Example 1 with compound 15-1.
  • the synthesis method refers to the synthesis of compound 1, to obtain compound 15.
  • Compound 21-1 is used to replace 12-1 in Example 12.
  • the synthesis method refers to the synthesis of compound 12 to obtain compound 21.
  • Compound 3-1 is used to replace 12-1 in Example 12, and the synthesis method refers to the synthesis of compound 12 to obtain compound 22.
  • Substitute compound 26-1 for compound 1-11 in Example 1, and the synthesis method refers to the synthesis of compound 1, to obtain compound 26.
  • Example 1 Replace acid 1-11 in Example 1 with compound 5-1, and replace 1-5 in Example 1 with compound 4-1.
  • the synthesis method refers to the synthesis of compound 1, to obtain compound 30.
  • Example 1 Replace acid 1-11 in Example 1 with compound 5-1, and replace 1-5 in Example 1 with compound 3-1.
  • the synthesis method refers to the synthesis of compound 1, to obtain compound 31.
  • Example 1 Replace acid 1-11 in Example 1 with compound 6-1, and replace 1-5 in Example 1 with compound 4-1.
  • the synthesis method refers to the synthesis of compound 1, to obtain compound 32.
  • Example 35 The compound 35-1 in Example 35 is replaced with compound 36-1, and the synthesis method refers to the synthesis of compound 35 to obtain compound 36.
  • Substitute compound 38-1 for compound 5-1 in Example 37 and refer to the synthesis of compound 12 for the synthesis method to obtain compound 38.
  • Substitute compound 60-1 for compound 1-8 in Example 5 Substitute compound 60-1 for compound 1-8 in Example 5.
  • the synthesis method refers to the synthesis of compound 9 to obtain compound 60.
  • Substitute compound 61-1 for compound 14-1 in Example 47 and refer to the synthesis of compound 47 for the synthesis method to obtain compound 61.
  • Example 12 Replace acid 5-1 in Example 12 with compound 64-1, and replace 12-1 in Example 1 with compound 8-1.
  • the synthesis method refers to the synthesis of compound 12 to obtain compound 64.
  • Compound 65-1 was used to replace acid 5-1 in Example 12, and compound 8-1 was used to replace 12-1 in Example 1.
  • the synthesis method refers to the synthesis of compound 12 to obtain compound 65.
  • Example 12 The acid 5-1 in Example 12 was replaced with compound 66-1, and 12-1 in Example 1 was replaced with compound 8-1.
  • the synthesis method refers to the synthesis of compound 12 to obtain compound 66.
  • Example 12 The acid 5-1 in Example 12 was replaced with compound 67-1, and 12-1 in Example 1 was replaced with compound 8-1.
  • the synthesis method refers to the synthesis of compound 12 to obtain compound 67.
  • Compound 68-1 was used to replace acid 5-1 in Example 12, and compound 8-1 was used to replace 12-1 in Example 1.
  • the synthesis method refers to the synthesis of compound 12 to obtain compound 68.
  • Example 12 Replace acid 5-1 in Example 12 with compound 24-1, and replace 12-1 in Example 1 with compound 8-1.
  • the synthesis method refers to the synthesis of compound 12 to obtain compound 69.
  • Example 12 Replace acid 5-1 in Example 12 with compound 10-1, and replace 12-1 in Example 1 with compound 8-1.
  • the synthesis method refers to the synthesis of compound 12 to obtain compound 70.
  • Compound 59-1 was used to replace acid 5-1 in Example 12, and compound 8-1 was used to replace 12-1 in Example 1.
  • the synthesis method refers to the synthesis of compound 12 to obtain compound 71.
  • Compound 72-1 was used to replace acid 1-11 in Example 1, and compound 8-1 was used to replace 1-5 in Example 1.
  • the synthesis method refers to the synthesis of compound 1, to obtain compound 72.
  • Example 1 Replace acid 1-11 in Example 1 with compound 11-1, and replace 1-5 in Example 1 with compound 8-1.
  • the synthesis method refers to the synthesis of compound 1, to obtain compound 73.
  • Example 1 Replace acid 1-11 in Example 1 with compound 74-1, and replace 1-5 in Example 1 with compound 8-1.
  • the synthesis method refers to the synthesis of compound 1, to obtain compound 74.
  • Example 1 Replace acid 1-11 in Example 1 with compound 25-1, and replace 1-5 in Example 1 with compound 8-1.
  • the synthesis method refers to the synthesis of compound 1, to obtain compound 75.
  • Example 1 Replace acid 1-11 in Example 1 with compound 2-1, and replace 1-5 in Example 1 with compound 8-1.
  • the synthesis method refers to the synthesis of compound 1, to obtain compound 76.
  • Example 1 Replace acid 1-11 in Example 1 with compound 65-1, and replace 1-5 in Example 1 with compound 8-1.
  • the synthesis method refers to the synthesis of compound 1, to obtain compound 77.
  • Example 1 The acid 1-11 in Example 1 was replaced with compound 13-1, and the synthesis method referred to the synthesis of compound 1, to obtain compound 78.
  • Example 1 The acid 1-11 in Example 1 was replaced with compound 14-1, and the synthesis method referred to the synthesis of compound 1, to obtain compound 79.
  • Example 1 The acid 1-11 in Example 1 was replaced with compound 80-1, and the synthesis method referred to the synthesis of compound 1, and compound 80 was obtained.
  • Example 12 The compound 12-1 in Example 12 was replaced with compound 4-1, and the synthesis method referred to the synthesis of compound 12 to obtain compound 82.
  • Test Example 1 Evaluation of the Inhibitory Activity of the 2019 Novel Coronavirus 3CL Protease
  • Fluorescence resonance energy transfer (FRET) technology was used to determine the enzyme level inhibitory activity against the 3C protease inhibitor.
  • FRET Fluorescence resonance energy transfer
  • Table 1A 2019 Novel Coronavirus 3CL Protease Inhibitory Activity
  • Table 1B Inhibition of the 3CL protease inhibitory activity of the 2019 novel coronavirus (IC 50 )
  • Test Example 2 Evaluation of the compound's 2019 novel coronavirus replication inhibitory activity and determination of its half-toxic concentration
  • the results showed that the compound in the patent was tested under different concentration gradients with CQ as a positive control, compound 2234 (DC402234, namely compound 48), 2259 (DC402259, namely compound 81), 2267 (DC402267, namely compound 16) Both have excellent anti-virus activity.
  • the EC 50 of 2234 is 0.29 ⁇ M, and the EC 50 of 2259 is 0.33 ⁇ 0.09 ⁇ M, respectively. Therefore, the inhibitory rate of compounds 48 and 81 on 2019-nCoV at the viral level is better than that of the positive control CQ, showing better anti-2019-nCoV potential ( Figure 2).
  • the CCK8 kit analysis was used to determine the half-toxic concentration (CC 50 ) of some of the compounds of the present invention on Vero E6 cells and re-measured.
  • SARS-CoV-2 3CL pro The full-length gene encoding SARS-CoV-2 3CL pro was optimized and synthesized, and inserted into the BamHI and XhoI sites of pGEX-6p-1 plasmid DNA (Amersham Biosciences) for use in Escherichia coli (E.coil ) Expression (GENEWIZ). SARS-CoV-2 3CL pro was further purified and then co-crystallized. SARS-CoV-2 3CL pro was incubated with 10 mM compound 48 or compound 81 for 30 min, and suspended droplet vapor diffusion method was used to crystallize at 20°C (5 mg/ml).
  • the best crystals were grown with a buffer containing 2% polyethylene glycol (PEG) 6000, 3% DMSO, 1 mM DTT, 0.1M MES (pH 6.0).
  • the cryoprotectant solution contains 30% PEG 400, 0.1M MES (pH 6.0).
  • the coordinates and structure factors of SARS-CoV-2 3CL pro and compounds 48 and 81 have been stored in the protein database, and the PDB numbers are 6LZE and 6M0K, respectively.
  • the main chain and side chain Glu166 of Phe140 also participates in stabilizing the five-membered ring lactam by forming hydrogen bonds with NH.
  • the amide bond on the main chain of compound 48 forms hydrogen bonds with the main chains of His164 and Glu166, respectively ( Figure 3B).
  • the cyclohexyl group of compound 48 penetrates into the S2 pocket and is surrounded by the side chains of Met49, Tyr54, Met165 and Asp187, resulting in extensive hydrophobic interactions (Figure 3B).
  • the indole group of compound 48 was exposed to the solvent (S4 pocket) and was stabilized by Glu166 through hydrogen bonding (Figure 3B).
  • the crystal structures of compound 81 and SARS-CoV-2 M pro are very similar to compound 48, showing similar inhibitor binding modes (Figure 3C, 3D).
  • the difference in binding may be caused by the aryl group of compound 81.
  • the aryl group of compound 81 Compared with the cyclohexyl group in compound 48, the aryl group of compound 81 has a significant rotation ( Figure 3C).
  • the side chains of His41, Met49, Met165, and Val186 residues interact with aryl groups through hydrophobic interactions (Figure 3D).
  • the side chain of Gln189 stabilizes the aryl group by forming an additional hydrogen bond with the fluorine atom ( Figure 3D).
  • these two crystal structures reveal the same inhibitory mechanism, that is, these two compounds occupy the substrate binding pocket, mimicking the intermediate in the catalytic reaction, and block the enzyme of SARS-CoV-2 M pro. active.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

如通式I所示的醛类化合物，及其药物组合物、药用盐、对映体、非对映体及外消旋化合物在作为2019新型冠状病毒（2019-nCov）3CL蛋白酶抑制剂在制备治疗和/或预防、缓解由2019新型冠状病毒感染引起的呼吸道感染、肺炎等相关疾病的药物中的用途。

Description

一种醛基类化合物的药物用途 技术领域
本发明涉及医药领域，具体地涉及一种醛基类化合物的医药用途。
背景技术
在急性传染病中，绝大部分都是病毒性传染病，病毒性传染病的发病率高，死亡率也很高。由于检测和诊断手段有限，导致新病毒引发的新疫情爆发往往具有突发性、随机性和不可预测性等特点，一旦爆发，如无有效的防治手段，极易造成大规模流行，严重威胁人民健康生命安全。2019年底，爆发新型冠状病毒(2019-nCoV，也称为SARS-CoV-2)感染，引起严重肺炎(Covid)，截止2020年1月28日10时，全国已感染4529例，死亡106例。2019-nCoV病毒传播途径未完全掌握，已知能通过飞沫和接触传播，且存在人传人、医务人员感染，一定社区传播风险，且病毒存在变异的可能。目前对于新型冠状病毒所致疾病没有特异的预防和治疗方法。
2019-nCoV冠状病毒属于冠状病毒科冠状病毒属，为具有包膜的单链正义RNA病毒。和其他已知冠状病毒类似，2019-nCoV冠状病毒也经过吸附、穿入、脱壳、生物合成、子代病毒的组装与释放等几个过程完成子代病毒的增殖。2019-nCoV冠状病毒感染宿主细胞起始于病毒包膜表面的刺突糖蛋白与宿主细胞表面的受体结合，随后发生膜融合，病毒进入宿主细胞，在细胞溶酶体等细胞器作用下，释放出病毒的遗传物质单链正义RNA，在宿主细胞的线粒体、核糖体等蛋白质合成元件以及必须的原料等作用下，翻译产生多聚蛋白，之后，2019-nCoV冠状病毒的两大必需半胱氨酸蛋白酶：木瓜样蛋白酶(papain-like protease,PL pro)和3C样蛋白酶(3C-like protease,3CL pro)在特定位点切割加工多聚蛋白前体，产生多个对病毒生命周期非常重要的非结构蛋白。在这些非结够蛋白的作用下，病毒RNA复制出子代病毒核酸物质，并大量翻译出所需的结构蛋白，完成子代病毒的组装和释放。2019-nCoV冠状病毒感染细胞的生命周期的任何环节或关键酶均可以作为抗病毒药物的研究靶点，如水解切割多聚蛋白前体的半胱氨酸蛋白酶PL pro和3CL pro，负责完成子代病毒遗传物质复制的RNA聚合酶等。
3CL蛋白酶(3 chymotrypsin-like protease,3CL pro)，又称主蛋白酶(M pro)，是冠状病毒RNA翻译出多聚蛋白pp1a和pp1ab后水解产生多个非结构蛋白过程中的关键蛋白酶，对病毒的复制和感染至关重要，抑制3CL蛋白酶的催化功能可有效抑制病毒多聚蛋白前体的切割，阻断病毒复制，抑制子代病毒生成。3CL pro属于半胱氨酸蛋白酶，是催化单正链RNA病毒前体蛋白水解的关键蛋白酶，对2019-nCoV等冠状病毒的复制活性具有重要的作用。因此，3CL pro是目前公认的研发抗冠状病毒药物的理想靶点。
目前，针对2019-nCoV冠状病毒导致的严重肺炎疾病尚无特效的疫苗和抗病毒 药物。这些感染性疾病严重影响了人们的生命健康，研发效果好的小分子抗病毒药物迫在眉睫。针对2019-nCoV冠状病毒3CL pro开发出结构新颖、低毒高效且具有自主知识产权的抗病毒药物，以满足国内外2019-nCoV冠状病毒感染患者的临床需求，具有重大的社会意义。
综上所述，本领域迫切需要开发针对2019-nCoV冠状病毒3CL蛋白酶的抑制剂用于治疗新型冠状病毒感染引起的肺炎。
发明内容
本发明的目的是提供一种醛基类化合物的新用途。
具体地，本发明提供了通式I所示的醛基类化合物作为2019新型冠状病毒(2019-nCov)3CL蛋白酶抑制剂在制备治疗和/或预防、缓解由2019新型冠状病毒感染引起的呼吸道感染、肺炎等相关疾病的药物中的用途。
在本发明第一方面，提供了一种通式(I)所示的醛基类化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体的用途，其特征在于，用于制备(a)2019新型冠状病毒(2019-nCov)3CL蛋白酶抑制剂；和(b)治疗和/或预防、缓解由2019新型冠状病毒(2019-nCov)感染引起的相关疾病的药物：
Figure PCTCN2020081481-appb-000001
其中，
手性碳原子C*、C* 2、C* 3、C* 4各自独立地为S型、R型，或其组合；
n＝0或1；
R 1选自未被取代或者被1-3个取代基取代的以下基团：C3～C7环烷基、三氟甲基、C2～C6炔基、4～7元杂环基、C5～C7芳基、5～7元杂芳基；所述杂环基和杂芳基各自含有1～3个选自氧、硫和氮的杂原子；所述的取代基各自独立地选自下组：卤素、C1～C4直链或支链烷基、C1～C4直链或支链烯基、C2～C4直链或支链炔基、C1～C4直链或支链烷氧基、C1～C4直链或支链烷基羰氧基、氰基、硝基、羟基、氨基、羟甲基、三氟甲基、羧基、巯基、C1-C4酰基、酰胺基、磺酰基、氨基磺酰基、C1-C4烷基取代的磺酰基，或者两个相邻的取代基连同与其连接的碳原子构成5-7元环；
R 2选自未被取代或者被1-3个取代基取代的以下基团：C3～C7环烷基、5～12元杂环基(优选为5～7元杂环基或6元芳基并5～7元杂环基)、C6～C12芳基、5～ 12元杂芳基、苯乙烯基、或-Cbz；其中，各个所述杂环基或杂芳基含有1～3个选自氧、硫和氮的杂原子；所述的取代基各自独立地选自卤素、C1～C6直链或支链烷基、C2～C6直链或支链烯基、C2～C6直链或支链炔基、C1～C6直链或支链烷氧基、C1～C6直链或支链烷基羰氧基、氰基、硝基、羟基、氨基、羟甲基、三氟甲基、羧基、巯基、C1-C4酰基、酰胺基、磺酰基、氨基磺酰基、C1-C4烷基取代的磺酰基，或者两个相邻的取代基连同与其连接的碳原子构成5-7元环；
R 3选自未被取代或者被1-3个取代基取代的以下基团：C1～C6直链或支链烷基、C1～C6直链或支链烷氧基、C3～C7环烷基、C6～C12芳基、5～12元杂芳基，其中所述杂芳基含有1～3个选自氧、硫和氮的杂原子；其中，所述的取代基各自独立地选自卤素、C1～C6直链或支链烷基、C2～C6直链或支链烯基、C2～C6直链或支链炔基、C1～C6直链或支链烷氧基、C1～C6直链或支链烷基羰氧基、氰基、硝基、羟基、氨基、羟甲基、三氟甲基、羧基、巯基、C1-C4酰基、酰胺基、磺酰基、氨基磺酰基、C1-C4烷基取代的磺酰基，或者两个相邻的取代基连同与其连接的碳原子构成5-7元环。
在另一优选例中，所述由2019新型冠状病毒感染引起的相关疾病选自下组：呼吸道感染、肺炎及其并发症、或其组合。
在另一优选例中，R 1选自未被取代或者被1-3个取代基取代的以下基团：三氟甲基、炔基、环丙烷基、环丁烷基、环戊烷基、环己烷基、苯基、噻吩基、吡唑基、噻唑基、吡啶基、呋喃基。
在另一优选例中，R 1选自未被取代或者被1-3个取代基取代的以下基团：三氟甲基、炔基、环丙烷基、环丁烷基、环戊烷基、环己烷基、苯基、噻吩基、吡唑基、噻唑基、吡啶基、呋喃基；和/或
R 2为未被取代或者被1-3个取代基取代的选自下组的基团：苯基、苯乙烯基、苯并杂环基、5～12元杂芳基；优选地，所述苯并杂环和5～12元杂芳环选自苯并二氧杂环戊烯、吲哚、异噁唑、2-氢丙吡喃、吡啶、吡唑、二氢咪唑并吡啶、咪唑并吡啶、苯并噻吩、二氢苯并二氧六环、喹喔林、苯并呋喃、吲唑、苯并咪唑、喹啉。
在另一优选例中，手性碳原子C*、C* 2、C* 3、C* 4中的一个或多个为S型。
在另一优选例中，手性碳原子C*、C* 2、C* 3、C* 4为S型；和/或
R 1选自未被取代或者被1-3个取代基取代的以下基团：三氟甲基、炔基、环丙烷基、环丁烷基、环戊烷基、环己烷基、苯基、噻吩基、吡唑基、噻唑基、吡啶基、呋喃基；和/或
R 2为未被取代或者被1-3个取代基取代的选自下组的基团：苯基、苯乙烯基、苯并杂环基、5～12元杂芳基；优选地，所述苯并杂环和5～12元杂芳环选自苯并二氧杂环戊烯、吲哚、异噁唑、2-氢丙吡喃、吡啶、吡唑、二氢咪唑并吡啶、咪唑并吡啶、苯并噻吩、二氢苯并二氧六环、喹喔林、苯并呋喃、吲唑、苯并咪唑、喹 啉；和/或
R 3选自未被取代或者被1-3个取代基取代的以下基团：C1～C6直链或支链烷基、C3～C7环烷基、苯基。
在另一优选例中，所示通式(I)中化合物选自下组：
表A
Figure PCTCN2020081481-appb-000002
Figure PCTCN2020081481-appb-000003
Figure PCTCN2020081481-appb-000004
Figure PCTCN2020081481-appb-000005
Figure PCTCN2020081481-appb-000006
Figure PCTCN2020081481-appb-000007
Figure PCTCN2020081481-appb-000008
Figure PCTCN2020081481-appb-000009
Figure PCTCN2020081481-appb-000010
Figure PCTCN2020081481-appb-000011
Figure PCTCN2020081481-appb-000012
Figure PCTCN2020081481-appb-000013
Figure PCTCN2020081481-appb-000014
Figure PCTCN2020081481-appb-000015
Figure PCTCN2020081481-appb-000016
Figure PCTCN2020081481-appb-000017
在本发明第二方面，提供了一种药物组合物，其包括(a)治疗有效量的通式(I)所示的醛基类化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体或前药，和(b)药学上可接受的载体，其中，通式(I)所示的醛基类化合物如本发明第一方面中所述。
在本发明第三方面，提供了本发明第二方面所述的药物组合物的用途，它用于制备治疗和/或预防、缓解由2019新型冠状病毒(2019-nCov)感染引起的相关疾病的药物。
在另一优选例中，所述由2019新型冠状病毒感染引起的相关疾病选自下组：呼吸道感染、肺炎及其并发症、或其组合。
在本发明第三方面，提供了一种通式(I)所示的醛基类化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体；
Figure PCTCN2020081481-appb-000018
其中，
手性碳原子C*、C* 2、C* 3、C* 4各自独立地为S型、R型，或其组合；
n＝0或1；
R 1选自未被取代或者被1-3个取代基取代的以下基团：C3～C7环烷基、三氟甲基、C2～C6炔基、4～7元杂环基、C5～C7芳基、5～7元杂芳基；所述杂环基和杂芳基各自含有1～3个选自氧、硫和氮的杂原子；所述的取代基各自独立地选自下组：卤素、C1～C4直链或支链烷基、C1～C4直链或支链烯基、C2～C4直链或支链炔基、C1～C4直链或支链烷氧基、C1～C4直链或支链烷基羰氧基、氰基、硝基、羟基、氨基、羟甲基、三氟甲基、羧基、巯基、C1-C4酰基、酰胺基、磺酰基、氨基磺酰基、C1-C4烷基取代的磺酰基，或者两个相邻的取代基连同与其连接的碳原子构成5-7元环；
R 2选自未被取代或者被1-3个取代基取代的以下基团：C3～C7环烷基、5～12元杂环基(优选为5～7元杂环基或6元芳基并5～7元杂环基)、C6～C12芳基、5～12元杂芳基、苯乙烯基、或-Cbz；其中，各个所述杂环基或杂芳基含有1～3个选自氧、硫和氮的杂原子；所述的取代基各自独立地选自卤素、C1～C6直链或支链烷基、C2～C6直链或支链烯基、C2～C6直链或支链炔基、C1～C6直链或支链烷氧基、C1～C6直链或支链烷基羰氧基、氰基、硝基、羟基、氨基、羟甲基、三氟甲基、羧基、巯基、C1-C4酰基、酰胺基、磺酰基、氨基磺酰基、C1-C4烷基取代的磺酰基，或者两个相邻的取代基连同与其连接的碳原子构成5-7元环；
R 3选自未被取代或者被1-3个取代基取代的以下基团：C1～C6直链或支链烷基、C1～C6直链或支链烷氧基、C3～C7环烷基、C6～C12芳基、5～12元杂芳基，其中所述杂芳基含有1～3个选自氧、硫和氮的杂原子；其中，所述的取代基各自独立地选自卤素、C1～C6直链或支链烷基、C2～C6直链或支链烯基、C2～C6直链或支链炔基、C1～C6直链或支链烷氧基、C1～C6直链或支链烷基羰氧基、氰基、硝基、羟基、氨基、羟甲基、三氟甲基、羧基、巯基、C1-C4酰基、酰胺基、磺酰基、氨基磺酰基、C1-C4烷基取代的磺酰基，或者两个相邻的取代基连同与其连接的碳原子构成5-7元环。
在另一优选例中，R 1选自未被取代或者被1-3个取代基取代的以下基团：三氟甲基、炔基、环丙烷基、环丁烷基、环戊烷基、环己烷基、苯基、噻吩基、吡唑基、噻唑基、吡啶基、呋喃基。
在另一优选例中，R 1选自未被取代或者被1-3个取代基取代的以下基团：三氟甲基、炔基、环丙烷基、环丁烷基、环戊烷基、环己烷基、苯基、噻吩基、吡唑基、噻唑基、吡啶基、呋喃基；和/或
R 2为未被取代或者被1-3个取代基取代的选自下组的基团：苯基、苯乙烯基、苯并杂环基、5～12元杂芳基；优选地，所述苯并杂环和5～12元杂芳环选自苯并二氧杂环戊烯、吲哚、异噁唑、2-氢丙吡喃、吡啶、吡唑、二氢咪唑并吡啶、咪唑 并吡啶、苯并噻吩、二氢苯并二氧六环、喹喔林、苯并呋喃、吲唑、苯并咪唑、喹啉。
在另一优选例中，手性碳原子C*、C* 2、C* 3、C* 4为S型；和/或
R 1选自未被取代或者被1-3个取代基取代的以下基团：三氟甲基、炔基、环丙烷基、环丁烷基、环戊烷基、环己烷基、苯基、噻吩基、吡唑基、噻唑基、吡啶基、呋喃基；和/或
R 2为未被取代或者被1-3个取代基取代的选自下组的基团：苯基、苯乙烯基、苯并杂环基、5～12元杂芳基；优选地，所述苯并杂环和5～12元杂芳环选自苯并二氧杂环戊烯、吲哚、异噁唑、2-氢丙吡喃、吡啶、吡唑、二氢咪唑并吡啶、咪唑并吡啶、苯并噻吩、二氢苯并二氧六环、喹喔林、苯并呋喃、吲唑、苯并咪唑、喹啉；和/或
R 3选自未被取代或者被1-3个取代基取代的以下基团：C1～C6直链或支链烷基、C3～C7环烷基、苯基。
在另一优选例中，所述通式(I)中化合物为表A中的化合物1～88。
在本发明的第五方面，提供了一种治疗、预防、和/或缓解由2019新型冠状病毒(2019-nCov)感染引起的相关疾病的方法，包括步骤：给需要的对象施用安全有效量的通式(I)所示的醛基类化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体，其中所述的通式(I)所示的醛基类化合物如上所述。
在另一优选例中，所述的对象为灵长目哺乳动物，如人。
在本发明的第六方面，提供了一种抑制2019新型冠状病毒(2019-nCov)的3CL蛋白酶的活性的方法，包括步骤：将通式(I)所示的醛基类化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体与2019-nCov的3CL蛋白酶接触，从而抑制2019-nCov的3CL蛋白酶的活性。
在另一优选例中，所述的方法是非治疗性和非诊断性的。
在另一优选例中，所述的方法是体外的。
在另一优选例中，所述的2019-nCov的3CL蛋白酶是重组的或2019-nCov表达的3CL蛋白酶。
应理解，在本发明范围内中，本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合，从而构成新的或优选的技术方案。限于篇幅，在此不再一一累述。
附图说明
图1显示了本发明化合物可抑制2019nCoV病毒的复制。
图2显示了本发明部分化合物抑制2019新型冠状病毒(2019-nCov)的抑制曲线和EC50值。
图3显示了化合物48、81与SARS-CoV-2 3Cl pro形成的晶体复合物的结构。
具体实施方式
本发明人经过广泛而深入的研究，通过大量筛选，首次意外地开发了一类可有效抑制2019新型冠状病毒(2019-nCov)的活性成分，即通式I所示的化合物或或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体。试验表明，本发明的活性成分可高效地抑制2019新型冠状病毒(2019-nCov)的3CL蛋白酶的活性，从而抑制2019-nCov的复制和活力。在此基础上完成了本发明。
术语
在本文中，除特别说明之处，术语“取代”指基团上的一个或多个氢原子被选自下组的取代基取代：C 1～C 10烷基、C 3～C 10环烷基、C 1～C 10烷氧基、卤素、羟基、羧基(-COOH)、C 1～C 10醛基、C 2～C 10酰基、C 2～C 10酯基、氨基、苯基；所述的苯基包括未取代的苯基或具有1-3个取代基的取代苯基，所述取代基选自：卤素、C 1-C 10烷基、氰基、OH、硝基、C 3～C 10环烷基、C 1～C 10烷氧基、氨基。
除特别说明之处，本发明的所有化合物之中，各手性碳原子可以任选地为R构型或S构型，或R构型和S构型的混合物。
术语“C1～C6烷基”指具有1～6个碳原子的直链或支链烷基，例如甲基、乙基、丙基、异丙基、丁基、异丁基、仲丁基、叔丁基、或类似基团。
术语“3-8元杂环基”指具有选自下组的1-3个杂原子的3～8元饱和环失去一个氢原子形成的基团：N、S、O；例如吡咯烷基、哌啶基、哌嗪基、吗啉基、或类似基团。
术语“6-10元芳基”指6～10元芳基失去一个氢原子形成的基团；例如苯基、萘基，或类似基团。
术语“5-10元杂芳基”指具有选自下组的1-3个杂原子的5～8元芳基失去一个氢原子形成的基团：N、S、O，其中每个杂芳基的环状体系可以是单环或多环的；例如吡咯基、吡啶基、噻吩基、呋喃基、咪唑基、嘧啶基、苯并噻吩基、吲哚基、咪唑并吡啶基、喹啉基或类似基团。
术语“C1～C6烷氧基”指具有1-6个碳原子的直链或支链烷氧基，例如甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基、异丁氧基、仲丁氧基、叔丁氧基、或类似基团。
术语“C2-C6酯基”指具有2-6个碳原子的R-O-C(＝O)-基团，如-COOCH 3、-COOC 2H 5、-COOC 3H 7、-COOC 4H 9，或类似基团。
术语“C2-C6烯基”指具有2-6个碳原子的烯烃失去一个或两个氢原子所形成的基团，所述的烯烃可以是单烯烃、二烯烃或三烯烃，例如-CH＝CH 2、-C 2H 4＝CH 2、-CH＝C 2H 4，或类似基团。
术语“卤素”指F、Cl、Br和I。
除非特别说明，本发明所描述的结构式意在包括所有的同分异构形式(如对映异构，非对映异构和几何异构体(或构象异构体)：例如含有不对称中心的R、S构型，双键的(Z)、(E)异构体和(Z)、(E)的构象异构体。因此本发明的化合物的单个立体化学异构体或其对映异构体、非对映异构体或几何异构体(或构象异构体)的混合物都属于本发明的范围。
术语“互变异构体”表示具有不同能量的结构同分异构体可以超过低能垒，从而互相转化。比如，质子互变异构体(即质子移变)包括通过质子迁移进行互变，如1H-吲唑与2H-吲唑、1H-苯并[d]咪唑与3H-苯并[d]咪唑，化合价互变异构体包括通过一些成键电子重组而进行互变。
在本文中，形如“C1～C6”，表示该基团可以具有1个至6个碳原子，例如1个、2个、3个、4个或5个。
活性成分
在本发明中，提供了一种可有效抑制2019新型冠状病毒(2019-nCov)复制的活性成分。该活性成分为通式I所示的化合物，该活性成分可有效预防、治疗和/或缓解2019-nCov相关疾病。
试验表明，本发明的活性成分可有效地抑制2019新型冠状病毒(2019-nCov)的3CL蛋白酶，从而抑制2019新型冠状病毒(2019-nCov)的复制，进而预防、治疗和/或缓解2019-nCov相关疾病。2019-nCov也被称为SARS-CoV-2。
应理解，本发明的活性成分包括通式(I)所示的醛基类化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体、或其前药。应理解，本发明的活性成分还包括通式(I)化合物的晶型、无定形化合物、以及氘代化合物等形式。
所述“药学上可接受的盐”为通式(I)化合物与无机酸或有机酸反应形成常规的无毒盐。例如，常规的无毒盐可通过通式(I)化合物与无机酸或有机酸反应制得，所述无机酸包括盐酸、氢溴酸、硫酸、硝酸、胺基磺酸和磷酸等，所述有机酸包括柠檬酸、酒石酸、乳酸、丙酮酸、乙酸、苯磺酸、对甲苯磺酸、甲磺酸、萘磺酸、乙磺酸、萘二磺酸、马来酸、苹果酸、丙二酸、富马酸、琥珀酸、丙酸、草酸、三氟乙酸、硬酯酸、扑酸、羟基马来酸、苯乙酸、苯甲酸、水杨酸、谷氨酸、抗坏血酸、对胺基苯磺酸、2-乙酰氧基苯甲酸和羟乙磺酸等；或者通式(I)化合物与丙酸、草酸、丙二酸、琥珀酸、富马酸、马来酸、乳酸、苹果酸、酒石酸、柠檬酸、天冬氨酸或谷氨酸形成酯后再与无机碱形成的钠盐、钾盐、钙盐、铝盐或铵盐；或者通式(I)化合物与有机碱形成的甲胺盐、乙胺盐或乙醇胺盐；或者通式(I)化合物与赖氨酸、精氨酸、鸟氨酸形成酯后再与盐酸、氢溴酸、氢氟酸、硫酸、硝酸或磷酸形成的对应的无机酸盐或与甲酸、乙酸、苦味酸、甲磺酸或乙磺酸形成的对应的有机酸盐。
药物组合物和应用
本发明还提供了以通式(I)所示的醛基类化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体及前药中的一种或多种的混合物为有效成分在制备治疗和/或预防、缓解由2019新型冠状病毒感染引起的呼吸道感染、肺炎等相关疾病的药物中的用途。
本发明所提供的药物组合物优选含有重量比为0.001-99wt％的活性成份，优选的比例是通式I化合物作为活性成分占总重量的0.1wt％～90wt％，其余部分为药学可接受的载体、稀释液或溶液或盐溶液。
需要的时候，在本发明药物中还可以加入一种或多种药学上可接受的载体。所述载体包括药学领域常规的稀释剂、赋形剂、填充剂、粘合剂、润湿剂、崩解剂、吸收促进剂、表面活性剂、吸附载体、润滑剂等。
本发明所提供的化合物和药物组合物可以是多种形式，如片剂、胶囊、粉剂、糖浆、溶液状、悬浮液和气雾剂等，并可以存在于适宜的固体或液体的载体或稀释液中和适宜的用于注射或滴注的消毒器具中。
本发明的药物组合物的各种剂型可按照药学领域的常规制备方法制备。其制剂配方的单位计量中通常包含0.05-400mg通式I化合物，优选地，制剂配方的单位计量中包含1mg-500mg通式I化合物。
本发明的化合物和药物组合物可对哺乳动物临床使用，包括人和动物，可以通过口、鼻、皮肤、肺或者胃肠道等的给药途径。最优选为口服。最优选日剂量为0.01-400mg/kg体重，一次性服用，或0.01-200mg/kg体重分次服用。不管用何种服用方法，个人的最佳剂量应依据具体的治疗而定。通常情况下是从小剂量开始，逐渐增加剂量一直到找到最适合的剂量。
本发明的药物或抑制剂可通过各种不同方式施用，例如可通过注射、喷射、滴鼻、滴眼、渗透、吸收、物理或化学介导的方法导入机体如肌肉、皮内、皮下、静脉、粘膜组织；或是被其他物质混合或包裹导入机体。
本发明的主要优点包括：
(a)本发明化合物可高效地抑制2019-nCoV 3CL蛋白酶，部分化合物的IC50值达到约70nM。
(b)本发明化合物在病毒水平上对2019-nCoV的抑制率优于阳性对照CQ，展现出较好的抗2019-nCoV潜力。
(c)本发明化合物的毒副作用低，成药性好。
下面结合具体实施例，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法，通常按照常规条件，或按照制造厂商所建议的条件。除非另外说明，否则百分比和份数按重量计算。
样品的分析数据由以下仪器测定：核磁共振由GEMINI-300型、Bruker AMX-400型和INVOA-600型核磁共振仪测定，TMS(四甲基硅烷)为内标，化学位移单位为ppm，耦合常数单位为Hz；质谱由Finnigan MAT-711型，MAT-95和LCQ-DECA型质谱仪以及IonSpec 4.7 Tesla质谱仪测定。
柱层析用硅胶200-300目(青岛海洋化工厂生产)；TLC硅胶板为烟台化工厂生产的HSGF-254型薄层层析预制板；石油醚沸程为60-90℃；采用紫外灯，碘缸显色。除另有说明外，以下实施例中所用常规试剂、药品均购自国药集团。实验中所用试剂及溶剂均按反应具体情况处理。
实施例1:化合物1的合成
Figure PCTCN2020081481-appb-000019
合成路线：
Figure PCTCN2020081481-appb-000020
化合物1-2的合成：
氩气保护下，将N-叔丁氧羰基-L-谷氨酸二甲酯1-1(6g，21.8mmol)溶于60mL无水四氢呋喃中，于-78℃条件下缓慢滴LiHMDS(1M in THF)的四氢呋喃溶液(47mL,47mmol)，滴加过程保持温度稳定在-78℃，约持续1小时。滴毕后在-78℃条件搅拌1小时。将溴乙腈(2.79g，23.3mmol)溶于20ml四氢呋喃中，随后将该溶液缓慢滴入到反应体系中，滴加过程持续1～2小时。控温-78℃，继续反应20小时。THL监测(碱性高锰酸钾显色)反应完毕后，向反应液中加入3mL甲醇及冰醋酸与四氢呋喃的混合溶液22.7mL(v/v＝1/7.5)淬灭反应，搅拌10min后升至室温。倾入40mL饱和氯化钠溶液充分搅拌，可见反应体系分层。分离有机层，并用乙酸乙酯(EA)萃取水相，合并有机层后用无水硫酸钠干燥，浓缩，柱层析分离(PE:EA＝4:1)得到淡黄色油状物1-2 3.9g，收率为58％。
化合物1-3的合成：
将化合物1-2(1g，3.15mmol)溶于无水甲醇25mL，冰浴下搅拌至0℃后加入六水合二氯化钴(450mg，1.89mmol)，溶液即变为紫红色。10min后分次少 量加入硼氢化钠(715mg，18.9mmol)，观察到溶液颜色变为紫黑色，反应液继续在冰浴下反应1h后转为室温反应。15h后用饱和NH 4Cl溶液5mL淬灭后继续搅拌10min，利用硅藻土滤除固体后将滤液减压蒸干，用水20mL和乙酸乙酯30×3mL萃取，合并有机相，以无水Na 2SO 4干燥1h后减压浓缩，柱层析分离[PE:EA＝1:2]得到白色粉末状固体化合物1-3 460mg，产率51％。
化合物1-4的合成：
将中间体1-3(1g，3.5mmol)溶于二氯甲烷中，在0℃条件下加入4M HCl二氧六环溶液(9mL,35mmol)，反应在室温条件下持续搅拌12h，然后将溶液蒸干得到中间体1-4直接进行下一步反应。
化合物1-6的合成：
将化合物1-5(1.1g,3.5mmol)溶于二氯甲烷(40mL)，将反应液冷却至-20℃，然后将HATU(1.9g,4.9mmol)加入反应液，搅拌二十分钟后将上一步得到的中间体1-4加入反应液，再次在-20℃搅拌30分钟，随后将DIPEA(1.7mL,10.5mmol)滴加入反应液。反应搅拌12h后，分别用氯化铵(40×3mL)、碳酸氢钠(40×3mL)以及氯化钠(40×3mL)萃取，合并有机相，以无水硫酸钠干燥1h后减压蒸馏，柱层析分离(DCM:CH3OH,40:1v/v)，得白色粉末固体化合物1-6 1.3g，产率83％。
化合物1-7的合成：
将化合物1-6(1.5g,3.5mmol)溶于二氯甲烷中，在0℃条件下加入4M HCl二氧六环溶液(9mL,35mmol)，反应在室温条件下持续搅拌12h，然后将溶液蒸干得到中间体1-7直接进行下一步反应。
化合物1-9的合成：
将化合物1-8(0.76g,3.5mmol)溶于二氯甲烷(40mL)，将反应液冷却至-20℃，然后将HATU(1.9g,4.9mmol)加入反应液，搅拌二十分钟后将上一步得到的中间体1-7加入反应液，再次在-20℃搅拌30分钟，随后将DIPEA(1.7mL,10.5mmol)滴加入反应液。反应搅拌12h后，分别用氯化铵(40×3mL)、碳酸氢钠(40×3mL)以及氯化钠(40×3mL)萃取，合并有机相，以无水硫酸钠干燥1h后减压蒸馏，柱层析分离(DCM:CH3OH,40:1v/v)，得白色粉末固体化合物1-9 1.6g，产率85％。
化合物1-10的合成：
将中间体1-9(1.86g,3.5mmol)溶于二氯甲烷中，在0℃条件下加入4M HCl二氧六环溶液(9mL,35mmol)，反应在室温条件下持续搅拌12h，然后将溶液蒸干得到中间体1-10直接进行下一步反应。
化合物1-12的合成：
将化合物1-11(0.61g,3.5mmol)溶于二氯甲烷(40mL)，将反应液冷却至-20℃，然后将HATU(1.9g,4.9mmol)加入反应液，搅拌二十分钟后将上一步得到的中间体(10)加入反应液，再次在-20℃搅拌30分钟，随后将DIPEA(1.7mL,10.5mmol)滴加入反应液。反应搅拌12h后，分别用氯化铵(40×3mL)、碳酸氢钠(40×3mL)以及氯化钠(40×3mL)萃取，合并有机相，以无水硫酸钠干燥1h后减压蒸馏，柱 层析分离(DCM:CH3OH,20:1v/v)，得白色粉末固体化合物(12)1.7g，产率81％。
化合物1-13的合成：
将化合物1-12(304mg,0.51mmol)溶于20ml二氯甲烷中，分批缓慢加入硼氢化钠(107mg,2.9mmol)，后逐滴加入甲醇1ml，室温下搅拌约2小时反应完全。待反应完毕后，加入约20ml饱和食盐水淬灭反应，加入二氯甲烷萃取。有机相经饱和食盐水洗涤、无水硫酸钠干燥后，柱层析分离(DCM:CH3OH,20:1v/v)，得到白色固体(13)216mg，产率74％
化合物1的合成：
将化合物1-12(165mg,0.29mmol)溶于20ml二氯甲烷溶于中，加入戴斯-马汀氧化剂(147mg,0.35mmol)，在室温下搅拌。TLC监测(紫外)反应完全后，反应液使用硫代硫酸钠萃取至澄清，后用无水硫酸钠干燥后浓缩。柱层析分离(DCM:CH3OH,20:1v/v)，得到化合物1共98mg，产率60％。
1H NMR(600MHz,Acetone-d6)δ9.30(s,1H),7.75(d,J＝9.0Hz,1H),7.66-7.57(m,3H),7.25(t,J＝7.8Hz,1H),7.07(s,1H),7.00-6.93(m,2H),6.55(t,J＝4.4Hz,1H),4.91(s,2H),4.76(dd,J＝9.1,6.5Hz,1H),4.28-4.14(m,2H),3.29(m,1H),3.16(m,1H),2.35(m,1H),2.11-1.95(m,3H),1.85-1.43(m,10H),1.40-1.18(m,5H),0.67(dd,J＝25.0,6.7Hz,6H).ESI-MS m/z 566.31[M+H] +
实施例2:化合物2的合成
Figure PCTCN2020081481-appb-000021
用化合物2-1替换实施例1中的酸1-11，合成方法参考化合物1的合成，得到化合物2。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),7.73(s,1H),7.67-7.59(m,3H),7.31-7.23(m,2H),6.91(d,J＝8.4Hz,1H),6.55(t,J＝4.4Hz,1H),4.91(s,2H),4.67(dd,J＝9.1,6.5Hz,1H),4.44(dt,J＝8.8,6.4Hz,1H),4.29(dt,J＝9.3,6.9Hz,1H),3.35-3.19(m,2H),2.53(m,1H),2.18(dt,J＝12.7,6.3Hz,1H),2.13-2.00(m,1H),1.97(dt,J＝12.9,6.4Hz,1H),1.91-1.68(m,4H),1.65-1.59(m,1H),1.59-1.44(m,3H),1.44-1.32(m,6H),1.23(m,2H),0.67(dd,J＝25.0,6.7Hz,6H).ESI-MS m/z 600.27[M+H] +
实施例3:化合物3的合成
Figure PCTCN2020081481-appb-000022
用化合物2-1替换实施例1中的酸1-11，3-1替换实施例1中1-5，合成方法参考化合物1的合成，得到化合物3。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),7.82(d,J＝9.2Hz,1H),7.74(s,1H),7.62(dd,J＝9.2,2.2Hz,2H),7.28(d,J＝8.4Hz,1H),7.23(s,1H),6.91(d,J＝8.4Hz,1H),6.55(t,J＝4.4Hz,1H),4.91(s,2H),4.78(dd,J＝9.1,6.5Hz,1H),4.32(dt,J＝9.0,6.4Hz,1H),4.19(dt,J＝9.3,6.9Hz,1H),3.29(m,1H),3.17(m,1H),2.35(m,1H),2.09(dt,J＝12.8,6.3Hz,1H),2.05-1.94(m,1H),1.94-1.87(m,1H),1.87-1.77(m,2H),1.77-1.67(m,3H),1.67-1.64(m,1H),1.64-1.56(m,3H),1.56-1.45(m,4H),0.67(dd,J＝25.0,6.7Hz,6H).ESI-MS m/z 586.26[M+H] +
实施例4:化合物4的合成
Figure PCTCN2020081481-appb-000023
用化合物4-1替换实施例3中3-1，合成方法参考化合物3的合成，得到化合物4。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),7.77(d,J＝9.3Hz,1H),7.66-7.58(m,3H),7.41(s,1H),7.31-7.22(m,3H),6.93(t,J＝8.1Hz,2H),6.82(d,J＝8.4Hz,1H),6.55(t,J＝4.4Hz,1H),4.97(dd,J＝9.2,6.6Hz,1H),4.91(s,2H),4.73(dt,J＝9.3,7.7Hz,1H),4.40(dt,J＝9.0,6.4Hz,1H),3.33(m,1H),3.21(m,1H),3.04(dd,J＝14.0,7.8Hz,1H),2.92(dd,J＝14.0,7.8Hz,1H),2.44(m,1H),2.16-2.01(m,2H),1.96-1.81(m,2H),1.73(m,1H),0.86(dd,J＝25.0,6.7Hz,6H).ESI-MS m/z 612.22[M+H] +
实施例5:化合物5的合成
Figure PCTCN2020081481-appb-000024
用化合物5-1替换实施例1中的酸1-11，合成方法参考化合物1的合成，得到化合物5。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),9.12(s,1H),8.55(d,J＝9.2Hz,1H),7.69-7.55(m,3H),7.44-7.32(m,2H),7.28-7.12(m,2H),6.55(t,J＝4.4Hz,1H),5.11(dd,J＝9.2,6.6Hz,1H),4.50-4.23(m,2H),3.34(m,1H),3.20(m,1H),2.40(m,1H),2.29-2.19(m,J＝6.7Hz,1H),2.14(dt,J＝12.9,6.4Hz,1H),1.99-1.70(m,5H),1.58-1.32(m,10H),1.26-1.18(m,2H),0.87(dd,J＝25.0,6.7Hz,6H).ESI-MS m/z 552.31[M+H] +
实施例6:化合物6的合成
Figure PCTCN2020081481-appb-000025
用化合物6-1替换实施例1中的酸1-11，合成方法参考化合物1的合成，得到化合物6。
1H NMR(600MHz,Acetone-d6)δ9.30(s,1H),8.18(d,J＝9.2Hz,1H),7.86(d,J＝9.3Hz,1H),7.65(d,J＝9.0Hz,1H),6.58-6.52(m,2H),5.18(dd,J＝9.1,6.5Hz,1H),4.41(dt,J＝8.8,6.3Hz,1H),4.33(dt,J＝9.3,6.9Hz,1H),3.31(m,1H),3.19(m,1H),2.47(s,3H),2.39(m,1H),2.18-2.04(m,2H),1.92(m,2H),1.82(m,1H),1.78-1.69(m,2H),1.55-1.43(m,5H),1.43-1.31(m,5H),1.19(m,2H),0.88(dd,J＝24.9,6.6Hz,6H).ESI-MS m/z 517.29[M+H] +
实施例7:化合物7的合成
Figure PCTCN2020081481-appb-000026
用化合物5-1替换实施例1中的酸1-11，化合物7-1替换实施例1中的化合物1-8，合成方法参考化合物1的合成，得到化合物7。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),8.28(d,J＝9.0Hz,1H),7.68(d,J＝9.3Hz,1H),7.65(d,J＝8.8Hz,1H),6.55(t,J＝4.4Hz,1H),6.39(d,J＝6.0Hz,1H),6.30(dd,J＝8.7,7.3Hz,1H),6.21(dd,J＝8.7,7.3Hz,1H),6.14(d,J＝8.6Hz,1H),6.06(dd,J＝8.7,5.7Hz,1H),5.84(dd,J＝8.7,5.3Hz,1H),4.61(dd,J＝25.3,9.0Hz,1H),4.50(dt,J＝9.3,6.9Hz,1H),4.31(dt,J＝8.8,6.4Hz,1H),3.77(dt,J＝8.6,5.2Hz,1H),3.37-3.29(m,2H),3.20(m,1H),2.41(m,1H),2.13(dt,J＝12.7,6.3Hz,1H),1.95-1.71(m,5H),1.65(t,J＝25.1Hz,6H),1.59-1.34(m,9H),1.29(m,2H).ESI-MS m/z 572.32[M+H] +.
实施例8:化合物8的合成
Figure PCTCN2020081481-appb-000027
用化合物6-1替换实施例1中的酸1-11，化合物8-1替换实施例1中1-5，合成方法参考化合物1的合成，得到化合物8。
1H NMR(600MHz,Acetone-d6)δ9.35(s,1H),8.30(d,J＝6.8Hz,1H),7.81-7.69(m,1H),7.58(d,J＝8.4Hz,1H),7.31-7.22(m,4H),7.17(t,J＝7.1Hz,1H),6.94(s,1H),6.52(d,J＝0.7Hz,1H),4.79(m,1H),4.54-4.43(m,1H),4.27(m,1H),3.32-3.18(m,3H),3.04(dd,J＝13.8,8.1Hz,1H),2.44-2.28(m,2H),2.22(dd,J＝13.4,6.7Hz,1H),1.93(d,J＝5.6Hz,1H),1.81-1.72(m,2H),1.31(s,2H),0.93(dd,J＝10.3,6.8Hz,6H).ESI-MS m/z 511.24[M+H] +.
实施例9:化合物9的合成
Figure PCTCN2020081481-appb-000028
用化合物5-1替换实施例1中的酸1-11，化合物8-1替换实施例1中1-5，合成方法参考化合物1的合成，得到化合物9。
1H NMR(600MHz,Acetone-d6)δ11.20(s,1H),9.46(s,1H),8.22(d,J＝7.4Hz,1H),7.96-7.88(m,1H),7.75(dd,J＝11.9,4.0Hz,1H),7.62(m,2H),7.33-7.29(m,1H),7.26-7.20(m,3H),7.19-7.06(m,4H),7.03(dd,J＝16.8,9.5Hz,1H),4.88-4.80(m,1H),4.54-4.32(m,2H),3.38(dd,J＝19.0,10.1Hz,1H),3.32-3.24(m,2H),3.00(m,1H),2.43(m,1H),2.32(m,2H),2.23(m,1H),1.87-1.81(m,1H),1.31(d,J＝1.7Hz,1H),0.96(dd,J＝10.7,6.9Hz,6H).ESI-MS m/z 546.26[M+H] +.
实施例10:化合物10的合成
Figure PCTCN2020081481-appb-000029
用化合物10-1替换实施例1中的酸1-11，化合物8-1替换实施例1中1-5，合成方法参考化合物1的合成，得到化合物10。
1H NMR(600MHz,Acetone-d6)δ9.21(s,2H),8.32(d,J＝9.2Hz,2H),7.74-7.67(m,4H),7.63(dd,J＝12.5,8.3Hz,4H),7.58(d,J＝9.3Hz,2H),7.39(t,J＝7.7Hz,2H),7.33-7.23(m,7H),7.23-7.18(m,1H),7.16-7.08(m,4H),6.55(t,J＝4.4Hz,2H),5.01(dd,J＝9.2,6.6Hz,2H),4.75(dt,J＝9.3,7.8Hz,2H),4.38(dt,J＝8.8,6.3Hz,2H),3.38-3.28(m,4H),3.26-3.10(m,4H),2.42(m,2H),2.28-2.16(m,J＝6.6Hz,2H),2.13(dt,J＝12.8,6.3Hz,2H),1.92(dt,J＝12.8,6.3Hz,2H),1.83(m,2H),1.74(m,2H),0.88(dd,J＝25.1,6.6Hz,12H).ESI-MS m/z 547.25[M+H] +.
实施例11:化合物11的合成
Figure PCTCN2020081481-appb-000030
用化合物11-1替换实施例1中的酸1-11，化合物8-1替换实施例1中1-5，合成方法参考化合物1的合成，得到化合物11。
1H NMR(600MHz,Acetone-d6)δ9.40(s,1H),8.74(d,J＝8.5Hz,1H),8.52(d,J＝8.5Hz,1H),8.27(d,J＝8.5Hz,1H),8.14(d,J＝8.5Hz,1H),8.06(d,J＝8.0Hz,1H),7.96(d,J＝8.0Hz,1H),7.88-7.82(m,1H),7.72(dd,J＝11.2,4.0Hz,1H),7.29(d,J＝7.4Hz,2H),7.19(t,J＝7.6Hz,2H),7.09(d,J＝7.5Hz,1H),4.85(dd,J＝11.2,5.0Hz,1H),4.62-4.55(m,1H),4.40-4.30(m,1H),3.33-3.20(m,3H),3.06-3.00(m,1H),2.50-2.41(m,1H),2.38-2.27(m,2H),2.06-2.00(m,1H),1.80(dt,J＝12.9,9.6Hz,2H),1.30(d,J＝5.1Hz,1H),0.99(dd,J＝19.0,6.8Hz,6H).ESI-MS m/z 547.25[M+H] +.
实施例12:化合物12的合成
Figure PCTCN2020081481-appb-000031
合成路线：
Figure PCTCN2020081481-appb-000032
化合物12-2的合成：
将化合物12-1(1.05g,3.5mmol)溶于二氯甲烷(40mL)，将反应液冷却至-20℃，然后将HATU(1.9g,4.9mmol)加入反应液，搅拌二十分钟后将化合物1-4加入反应液，再次在-20℃搅拌30分钟，随后将DIPEA(1.7mL,10.5mmol)滴加入反应液。反应搅拌12h后，分别用氯化铵(40×3mL)、碳酸氢钠(40×3mL)以及氯化钠(40×3mL)萃取，合并有机相，以无水硫酸钠干燥1h后减压蒸馏，柱层析分离(DCM:CH3OH,40:1v/v)，得白色粉末固体化合物12-2 1.3g，产率79％。
化合物12-3的合成：
将化合物12-2(1.64g,3.5mmol)溶于二氯甲烷中，在0℃条件下加入4M HCl二氧六环溶液(9mL,35mmol)，反应在室温条件下持续搅拌12h，然后将溶液蒸干得到化合物12-3直接进行下一步反应。
化合物12-4的合成：
将化合物5-1(0.56g,3.5mmol)溶于二氯甲烷(40mL)，将反应液冷却至-20℃，然后将HATU(1.9g,4.9mmol)加入反应液，搅拌二十分钟后将上一步得到的中间体12-3加入反应液，再次在-20℃搅拌30分钟，随后将DIPEA(1.7mL,10.5mmol) 滴加入反应液。反应搅拌12h后，分别用氯化铵(40×3mL)、碳酸氢钠(40×3mL)以及氯化钠(40×3mL)萃取，合并有机相，以无水硫酸钠干燥1h后减压蒸馏，柱层析分离(DCM:CH3OH,40:1v/v)，得白色粉末固体化合物12-4 1.4g，产率78％。
化合物12-5的合成：
将化合物12-4(261mg,0.51mmol)溶于20ml二氯甲烷中，分批缓慢加入硼氢化钠(107mg,2.9mmol)，后逐滴加入甲醇1ml，室温下搅拌约2小时反应完全。待反应完毕后，加入约20ml饱和食盐水淬灭反应，加入二氯甲烷萃取。有机相经饱和食盐水洗涤、无水硫酸钠干燥后，柱层析分离(DCM:CH3OH,20:1v/v)，得到白色固体化合物12-5173mg，产率70％
化合物12的合成：
将化合物12-5 140mg,0.29mmol)溶于20ml二氯甲烷溶于中，加入戴斯-马汀氧化剂(147mg,0.35mmol)，在室温下搅拌。TLC监测(紫外)反应完全后，反应液使用硫代硫酸钠萃取至澄清，后用无水硫酸钠干燥后浓缩。柱层析分离(DCM:CH3OH,20:1v/v)，得到化合物12,共84mg，产率60％。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),9.11(s,1H),8.63(d,J＝9.3Hz,1H),7.79(d,J＝8.8Hz,1H),7.66(d,J＝7.7Hz,1H),7.54(s,1H),7.39(d,J＝7.9Hz,1H),7.25-7.13(m,3H),7.06(m,2H),6.55(t,J＝4.4Hz,1H),5.01(dt,J＝9.3,7.8Hz,1H),4.40(dt,J＝8.9,6.4Hz,1H),3.31(m,1H),3.19(m,1H),3.07(dd,J＝14.0,7.8Hz,1H),2.96(dd,J＝13.9,7.7Hz,1H),2.41(m,1H),2.16(dt,J＝12.8,6.3Hz,1H),1.92(dt,J＝12.9,6.4Hz,1H),1.84-1.70(m,2H).ESI-MS m/z 482.18[M+H] +
实施例13:化合物13的合成
Figure PCTCN2020081481-appb-000033
用化合物13-1替换实施例11中的化合物11-1，合成方法参考化合物11的合成，得到化合物13。
1H NMR(600MHz,Acetone-d6)δ9.37(s,1H),9.21(s,1H),8.47(d,J＝9.1Hz,1H),7.63(d,J＝8.8Hz,1H),7.58(d,J＝9.3Hz,1H),7.50(d,J＝8.4Hz,1H),7.38(s,1H),7.29(s,1H),7.28-7.20(m,3H),7.14-7.09(m,2H),6.80(d,J＝8.4Hz,1H),6.55(t,J＝4.4Hz,1H),4.98(dd,J＝9.2,6.6Hz,1H),4.74(dt,J＝9.3,7.8Hz,1H),4.39(dt,J＝8.8,6.4Hz,1H),3.83(s,3H),3.39-3.29(m,2H),3.27-3.10(m,2H),2.44(m,1H),2.26(m,1H),2.11(dt,J＝12.7,6.3Hz,1H),1.94(dt,J＝12.9,6.4Hz,1H),1.83(m,1H),1.75(m,1H),0.88(dd,J＝25.0,6.7Hz,6H).ESI-MS m/z 576.27[M+H] +.
实施例14:化合物14的合成
Figure PCTCN2020081481-appb-000034
用化合物14-1替换实施例11中的化合物11-1，合成方法参考化合物11的合成，得到化合物14。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),9.04(s,1H),8.44(d,J＝9.2Hz,1H),7.67(s,1H),7.63(dd,J＝9.1,3.9Hz,2H),7.43(d,J＝10.3Hz,2H),7.28-7.20(m,3H),7.14-7.08(m,2H),6.55(t,J＝4.4Hz,1H),4.93(dd,J＝9.2,6.6Hz,1H),4.71(dt,J＝9.3,7.7Hz,1H),4.42(dt,J＝9.0,6.4Hz,1H),3.38-3.29(m,2H),3.23-3.11(m,2H),2.40(m,1H),2.18(m,2H),1.97(dt,J＝12.9,6.4Hz,1H),1.85(m,1H),1.74(m,1H),0.90(dd,J＝25.0,6.7Hz,6H).ESI-MS m/z 614.18[M+H] +
实施例15:化合物15的合成
Figure PCTCN2020081481-appb-000035
用化合物5-1替换实施例1中的酸1-11，化合物15-1替换实施例1中1-5，合成方法参考化合物1的合成，得到化合物15。
1H NMR(600MHz,Acetone-d6)δ9.30(s,2H),9.12(s,2H),8.54(d,J＝9.0Hz,2H),7.64(dd,J＝12.7,8.3Hz,4H),7.58(d,J＝9.3Hz,2H),7.42-7.36(m,4H),7.22(t,J＝7.5Hz,2H),7.19-7.13(m,2H),6.55(t,J＝4.4Hz,2H),4.92(dd,J＝9.1,6.5Hz,2H),4.68(m,1H),4.58(m,1H),4.46-4.33(m,4H),3.33(m,2H),3.21(m,2H),2.41(m,2H),2.19(m,2H),2.12(dd,J＝12.9,6.4Hz,2H),2.01-1.55(m,22H),1.47-1.38(m,2H),1.32(m,4H),0.87(dd,J＝25.0,6.7Hz,12H).ESI-MS m/z 569.30[M+H] +
实施例16:化合物16的合成
Figure PCTCN2020081481-appb-000036
用化合物11-1替换实施例1中的化合物1-11，合成方法参考化合物1的合成，得到化合物16。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),8.61(d,J＝9.2Hz,1H),8.30(s,2H),8.15(d,J＝8.1Hz,1H),7.95(d,J＝7.5Hz,1H),7.84(dd,J＝8.2,7.4Hz,1H),7.72-7.49(m,3H),6.55(t,J＝4.4Hz,1H),4.78(dd,J＝9.0,6.6Hz,1H),4.46-4.28(m,2H),3.33(m,1H),3.23(m,1H),2.54(m,1H),2.27-2.16(m,J＝6.6Hz,1H),2.11(dt,J＝12.8,6.3Hz,1H),2.02-1.90(m,3H),1.89-1.80(m,2H),1.74(m,1H),1.62-1.47(m,5H),1.45-1.24(m,5H),0.88(dd,J＝25.0,6.7Hz,6H).ESI-MS m/z 564.31[M+H] +.
实施例17:化合物17的合成
Figure PCTCN2020081481-appb-000037
用化合物10-1替换实施例1中的化合物1-11，合成方法参考化合物1的合成，得到化合物17。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),8.32(d,J＝9.2Hz,1H),7.71(s,1H),7.68-7.56(m,4H),7.39(t,J＝7.7Hz,1H),7.29(t,J＝7.5Hz,1H),6.55(t,J＝4.4Hz,1H),4.82(dd,J＝9.0,6.6Hz,1H),4.50(dt,J＝9.3,6.9Hz,1H),4.37(dt,J＝8.8,6.3Hz,1H),3.32(m,1H),3.19(m,1H),2.40(m,1H),2.22-2.08(m,2H),1.92(dt,J＝12.9,6.4Hz,1H),1.88-1.79(m,2H),1.78-1.68(m,2H),1.58(m,2H),1.54-1.37(m,7H),1.27(m,2H),0.88(dd,J＝25.0,6.7Hz,6H).ESI-MS m/z553.29[M+H] +.
实施例18:化合物18的合成
Figure PCTCN2020081481-appb-000038
用化合物18-1替换实施例1中的化合物1-11，合成方法参考化合物1的合成，得到化合物18。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),8.44(d,J＝9.2Hz,1H),7.66-7.58(m,3H),7.55(d,J＝7.9Hz,1H),7.46(d,J＝7.9Hz,1H),7.19(t,J＝7.8Hz,1H),6.55(t,J＝4.4Hz,1H),4.85(dd,J＝9.2,6.6Hz,1H),4.41(dt,J＝9.0,6.3Hz,1H),4.34(dt,J＝9.3,6.9Hz,1H),3.33(m,1H),3.23(m,1H),2.51(m,1H),2.26(m,1H),2.12(dt,J＝12.8,6.3Hz,1H),1.94 (dt,J＝12.9,6.4Hz,1H),1.86-1.43(m,11H),1.39-1.17(m,6H),0.90(dd,J＝25.0,6.7Hz,6H).ESI-MS m/z 631.20[M+H] +.
实施例19:化合物18的合成
Figure PCTCN2020081481-appb-000039
用化合物19-1替换实施例1中的化合物1-11，合成方法参考化合物1的合成，得到化合物19。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),8.36(d,J＝9.0Hz,1H),8.28(s,1H),8.07(d,J＝8.1Hz,1H),7.81-7.74(m,2H),7.62(dd,J＝9.2,4.4Hz,2H),7.52(t,J＝7.7Hz,1H),6.55(t,J＝4.4Hz,1H),4.74(dd,J＝9.2,6.6Hz,1H),4.38(dt,J＝9.3,6.9Hz,1H),4.29(dt,J＝8.8,6.4Hz,1H),3.35(m,1H),3.18(m,1H),2.49(s,3H),2.38(m,1H),2.29-2.10(m,2H),1.99-1.90(m,1H),1.87-1.69(m,4H),1.66-1.54(m,3H),1.54-1.34(m,6H),1.30-1.20(m,2H),0.88(dd,J＝25.1,6.6Hz,6H).ESI-MS m/z 578.33[M+H] +.
实施例20:化合物20的合成
Figure PCTCN2020081481-appb-000040
用化合物20-1替换实施例1中的化合物1-11，合成方法参考化合物1的合成，得到化合物20。
1H NMR(600MHz,Acetone-d6)δ9.30(s,1H),8.31(d,J＝9.0Hz,1H),7.82(s,1H),7.76-7.71(m,2H),7.60(dd,J＝11.4,9.1Hz,2H),7.42(d,J＝8.4Hz,1H),6.55(t,J＝4.4Hz,1H),5.16(dd,J＝9.0,6.6Hz,1H),4.48-4.29(m,2H),3.27(m,2H),2.41(m,1H),2.21(m,1H),2.13(dt,J＝12.8,6.3Hz,1H),2.00-1.86(m,2H),1.83(m,1H),1.78-1.67(m,3H),1.50(m,2H),1.47-1.33(m,6H),1.18(m,2H),0.88(dd,J＝25.0,6.7Hz,6H).ESI-MS m/z 587.26[M+H] +.
实施例21:化合物21的合成
Figure PCTCN2020081481-appb-000041
用化合物21-1替换实施例12中的12-1，合成方法参考化合物12的合成，得到化合物21。
1H NMR(500MHz,Chloroform)δ9.72(s,4H),8.62(s,4H),8.40(s,4H),7.98(s,4H),7.60(s,4H),7.23(s,4H),7.10(s,3H),6.98(s,3H),6.03(s,4H),5.82(s,4H),5.70(s,4H),5.04(s,2H),3.65(s,2H),3.55(s,2H),2.87(d,J＝12.0Hz,5H),2.61(s,3H),2.23(s,3H),2.02(s,4H),1.93(d,J＝15.1Hz,6H).ESI-MS m/z 395.16[M+H] +.
实施例22:化合物22的合成
Figure PCTCN2020081481-appb-000042
用化合物3-1替换实施例12中的12-1，合成方法参考化合物12的合成，得到化合物22。
1H NMR(500MHz,Chloroform)δ9.72(s,7H),8.63(s,7H),7.98(s,7H),7.60(s,7H),7.10(s,6H),7.00(d,J＝18.2Hz,14H),6.62(s,7H),6.16(s,7H),6.02(s,7H),5.29(s,5H),4.65(s,4H),3.65(s,4H),3.55(s,4H),2.80(s,4H),2.22(s,5H),2.02(s,13H),1.91(s,3H),1.76(s,13H),1.64(d,J＝15.3Hz,18H),1.53(s,3H),1.33(s,7H).ESI-MS m/z 439.23[M+H] +.
实施例23:化合物23的合成
Figure PCTCN2020081481-appb-000043
用化合物8-1替换实施例12中的12-1，23-1替换5-1，合成方法参考化合物12的合成，得到化合物23。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),8.31(d,J＝9.0Hz,1H),7.75(s,1H),7.61(m,3H),7.41(d,J＝8.1Hz,1H),7.29-7.19(m,3H),7.16-7.06(m,3H),6.55(t,J＝4.4Hz,1H),4.84(dt,J＝9.3,7.8Hz,1H),4.68(dd,J＝9.2,6.6Hz,1H), 4.36(dt,J＝9.0,6.4Hz,1H),3.38-3.27(m,2H),3.22-3.10(m,2H),2.39(m,1H),2.14(dt,J＝12.8,6.3Hz,1H),2.05(m,1H),1.91(dt,J＝12.7,6.3Hz,1H),1.83(m,1H),1.74(m,1H),0.88(dd,J＝25.0,6.7Hz,6H).ESI-MS m/z 564.24[M+H] +.
实施例24:化合物24的合成
Figure PCTCN2020081481-appb-000044
用化合物24-1替换实施例1中的化合物1-11，合成方法参考化合物1的合成，得到化合物24。
1H NMR(600MHz,Acetone-d6)δ9.30(s,1H),8.30(s,1H),8.24(d,J＝9.0Hz,1H),7.99-7.93(m,1H),7.80-7.75(m,1H),7.63(d,J＝9.0Hz,1H),7.58(d,J＝9.3Hz,1H),7.37-7.32(m,2H),6.55(t,J＝4.4Hz,1H),5.16(dd,J＝9.0,6.6Hz,1H),4.39(m,2H),3.33(m,1H),3.21(m,1H),2.42(m,1H),2.21-2.08(m,2H),1.99-1.87(m,2H),1.83(m,1H),1.78-1.66(m,3H),1.52(m,2H),1.47-1.28(m,6H),1.20(m,2H),0.86(dd,J＝25.1,6.6Hz,6H).ESI-MS m/z569.27[M+H] +.
实施例25:化合物25的合成
Figure PCTCN2020081481-appb-000045
用化合物25-1替换实施例1中的化合物1-11，合成方法参考化合物1的合成，得到化合物25。
实施例26:化合物26的合成
Figure PCTCN2020081481-appb-000046
用化合物26-1替换实施例1中的化合物1-11，合成方法参考化合物1的合成，得到化合物26。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),8.60(d,J＝9.0Hz,1H),8.30-8.19(m,3H),7.90(d,J＝8.4Hz,1H),7.70(d,J＝8.4Hz,1H),7.63 (dd,J＝9.2,4.9Hz,2H),6.55(t,J＝4.4Hz,1H),4.90(dd,J＝9.1,6.5Hz,1H),4.41(dt,J＝9.0,6.4Hz,1H),4.30(dt,J＝9.3,6.9Hz,1H),3.34(m,1H),3.23(m,1H),2.47(m,1H),2.26-2.16(m,J＝6.6Hz,1H),2.12(dt,J＝12.9,6.4Hz,1H),1.94(dt,J＝12.9,6.4Hz,1H),1.90-1.78(m,3H),1.74(m,1H),1.68-1.57(m,1H),1.54-1.41(m,4H),1.41-1.34(m,4H),1.22(m,2H),0.90(dd,J＝25.0,6.7Hz,6H).ESI-MS m/z 642.22[M+H] +.
实施例27:化合物27的合成
Figure PCTCN2020081481-appb-000047
用化合物24-1替换实施例1中的化合物1-11，8-1替换实施例1中的1-5合成方法参考化合物1的合成，得到化合物27。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),8.34(s,1H),8.20(d,J＝9.2Hz,1H),7.98-7.93(m,1H),7.80-7.75(m,1H),7.61(dd,J＝19.5,9.1Hz,2H),7.38-7.32(m,2H),7.29-7.20(m,3H),7.15-7.08(m,2H),6.55(t,J＝4.4Hz,1H),5.14(dd,J＝9.1,6.5Hz,1H),4.74(dt,J＝9.3,7.7Hz,1H),4.39(dt,J＝8.8,6.4Hz,1H),3.42-3.26(m,2H),3.24-3.07(m,2H),2.34(m,1H),2.20-2.06(m,2H),1.94(dt,J＝12.7,6.3Hz,1H),1.82(m,1H),1.74(m,1H),0.86(dd,J＝25.1,6.6Hz,6H).ESI-MS m/z 562.22[M+H] +.
实施例28:化合物28的合成
Figure PCTCN2020081481-appb-000048
用化合物28-1替换实施例9中的化合物1-8，合成方法参考化合物9的合成，得到化合物28。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),9.16(s,1H),8.46(d,J＝9.2Hz,1H),7.68-7.56(m,3H),7.39(d,J＝7.9Hz,1H),7.32(s,1H),7.29-7.14(m,5H),7.14-7.08(m,2H),6.55(t,J＝4.4Hz,1H),4.90(dd,J＝9.1,6.5Hz,1H),4.72(dt,J＝9.3,7.8Hz,1H),4.44(dt,J＝9.0,6.3Hz,1H),3.40-3.30(m,2H),3.21(m,1H),3.12(dd,J＝14.0,7.8Hz,1H),2.43(m,1H),2.17(dt,J＝12.8,6.3Hz,1H),1.97-1.80(m,3H),1.79-1.61(m,2H),1.46(m,1H),0.90-0.83(m,6H).ESI-MS m/z 559.28[M+H] +.
实施例29:化合物29的合成
Figure PCTCN2020081481-appb-000049
用化合物28-1替换实施例5中的化合物1-8，合成方法参考化合物5的合成，得到化合物29。
1H NMR(600MHz,Acetone-d6)δ9.30(s,1H),9.16(s,1H),8.46(d,J＝9.2Hz,1H),7.68-7.60(m,3H),7.44(s,1H),7.39(d,J＝7.9Hz,1H),7.22(t,J＝7.5Hz,1H),7.19-7.14(m,1H),6.55(t,J＝4.4Hz,1H),4.83(dd,J＝9.0,6.5Hz,1H),4.41(dt,J＝8.9,6.4Hz,1H),4.30(dt,J＝9.3,6.9Hz,1H),3.38-3.10(m,2H),2.42(m,1H),2.08(dt,J＝12.9,6.4Hz,1H),2.00-1.91(m,2H),1.86-1.62(m,5H),1.60-1.42(m,7H),1.35-1.20(m,5H),0.91-0.84(m,6H).ESI-MS m/z 565.33[M+H] +.
实施例30:化合物30的合成
Figure PCTCN2020081481-appb-000050
用化合物5-1替换实施例1中的酸1-11，化合物4-1替换实施例1中1-5，合成方法参考化合物1的合成，得到化合物30。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),9.12(s,1H),8.48(d,J＝9.0Hz,1H),7.68-7.56(m,3H),7.45(s,1H),7.39(d,J＝7.9Hz,1H),7.31-7.13(m,4H),7.02-6.95(m,2H),6.55(t,J＝4.4Hz,1H),4.99(dd,J＝9.2,6.6Hz,1H),4.75(dt,J＝9.2,7.7Hz,1H),4.39(dt,J＝8.8,6.4Hz,1H),3.33(m,1H),3.22(m,1H),3.04(dd,J＝14.1,7.7Hz,1H),2.92(dd,J＝14.0,7.8Hz,1H),2.44(m,1H),2.33-2.18(m,J＝6.6Hz,1H),2.12(dt,J＝12.8,6.3Hz,1H),1.94(dt,J＝12.9,6.3Hz,1H),1.83(m,1H),1.74(m,1H),0.88(dd,J＝25.0,6.7Hz,6H).ESI-MS m/z 563.25[M+H] +.
实施例31:化合物31的合成
Figure PCTCN2020081481-appb-000051
用化合物5-1替换实施例1中的酸1-11，化合物3-1替换实施例1中1-5，合 成方法参考化合物1的合成，得到化合物31。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),9.12(s,1H),8.55(d,J＝9.2Hz,1H),7.71-7.61(m,3H),7.39(d,J＝7.9Hz,1H),7.32(s,1H),7.24-7.14(m,2H),6.55(t,J＝4.4Hz,1H),5.02(dd,J＝9.1,6.5Hz,1H),4.41(dt,J＝9.0,6.4Hz,1H),4.30(dt,J＝9.3,6.9Hz,1H),3.34(m,1H),3.23(m,1H),2.47(m,1H),2.27-2.07(m,2H),1.95(dt,J＝12.9,6.4Hz,1H),1.88-1.79(m,3H),1.78-1.63(m,4H),1.59-1.48(m,5H),0.87(dd,J＝25.0,6.7Hz,6H).ESI-MS m/z 537.29[M+H] +.
实施例32:化合物32的合成
Figure PCTCN2020081481-appb-000052
用化合物6-1替换实施例1中的酸1-11，化合物4-1替换实施例1中1-5，合成方法参考化合物1的合成，得到化合物32。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),8.17(d,J＝9.0Hz,1H),7.98(d,J＝9.3Hz,1H),7.72(d,J＝8.8Hz,1H),7.28(dd,J＝8.4,4.9Hz,2H),7.03(t,J＝8.2Hz,2H),6.58-6.52(m,2H),4.75(dd,J＝9.0,6.6Hz,1H),4.58-4.44(m,2H),3.30(m,1H),3.18(m,1H),3.09(dd,J＝13.9,7.7Hz,1H),2.92(dd,J＝14.1,7.7Hz,1H),2.55-2.47(m,4H),2.24-2.11(m,J＝6.6Hz,1H),2.01(dt,J＝12.8,6.3Hz,1H),1.87-1.76(m,2H),1.73(m,1H),0.88(dd,J＝25.0,6.7Hz,6H).ESI-MS m/z 529.23[M+H] +.
实施例33:化合物33的合成
Figure PCTCN2020081481-appb-000053
用化合物33-1替换实施例9中的化合物1-8，合成方法参考化合物9的合成，得到化合物33。
1H NMR(600MHz,Acetone-d6)δ9.30(s,1H),9.12(s,1H),8.49(d,J＝8.8Hz,1H),7.81(d,J＝9.3Hz,1H),7.69-7.60(m,2H),7.41(d,J＝7.9Hz,1H),7.32-7.08(m,8H),6.55(t,J＝4.4Hz,1H),4.79(dt,J＝9.3,7.7Hz,1H),4.48(dt,J＝9.0,6.3Hz,1H),4.42(d,J＝8.8Hz,1H),3.37-3.30(m,2H),3.24-3.11(m,2H),2.43(m,1H),2.24(dt,J＝12.7,6.3Hz,1H),1.99 (dt,J＝12.9,6.3Hz,1H),1.87-1.71(m,2H),0.98(s,9H).ESI-MS m/z 559.28[M+H] +.
实施例34:化合物34的合成
Figure PCTCN2020081481-appb-000054
用化合物33-1替换实施例5中的化合物1-8，合成方法参考化合物9的合成，得到化合物34。
1H NMR(600MHz,Acetone-d6)δ9.30(s,1H),9.12(s,1H),8.53(d,J＝8.8Hz,1H),7.69-7.55(m,3H),7.39(d,J＝7.9Hz,1H),7.35(s,1H),7.22(t,J＝7.5Hz,1H),7.19-7.12(m,1H),6.55(t,J＝4.4Hz,1H),4.61-4.55(m,2H),4.33(dt,J＝9.3,6.8Hz,1H),3.34(m,1H),3.22(m,1H),2.46(m,1H),2.06(dt,J＝12.8,6.3Hz,1H),1.98-1.79(m,3H),1.78-1.58(m,5H),1.57-1.39(m,3H),1.34-1.17(m,5H),0.98(s,9H).ESI-MS m/z 565.33[M+H] +.
实施例35:化合物35的合成
Figure PCTCN2020081481-appb-000055
用化合物5-1替换实施例1中的化合物1-11，化合物35-1替换实施例1中1-5，合成方法参考化合物1的合成，得到化合物35。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),9.12(s,1H),8.54(d,J＝9.0Hz,1H),7.67-7.56(m,3H),7.42-7.36(m,2H),7.23(t,J＝7.6Hz,1H),7.16(dd,J＝8.0,7.4Hz,1H),6.55(t,J＝4.4Hz,1H),4.89(dd,J＝9.0,6.6Hz,1H),4.74-4.52(m,2H),4.52-4.43(m,1H),4.33(dt,J＝8.8,6.4Hz,1H),3.33(m,1H),3.19(m,1H),2.40(m,1H),2.20(m,1H),2.15-2.09(m,1H),2.00-1.56(m,12H),0.87(dd,J＝25.0,6.7Hz,6H).ESI-MS m/z 587.29[M+H] +.
实施例36:化合物36的合成
Figure PCTCN2020081481-appb-000056
用化合物36-1替换实施例35中的化合物35-1，合成方法参考化合物35的合成，得到化合物36。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),9.07(s,1H),8.54(d,J＝9.2Hz,1H),7.73-7.62(m,3H),7.39(d,J＝7.9Hz,1H),7.32(s,1H),7.25-7.14(m,2H),6.55(s,1H),4.99(dd,J＝9.2,6.6Hz,1H),4.46(dt,J＝8.8,6.4Hz,1H),4.42-4.32(m,1H),3.38-3.18(m,2H),2.45(t,J＝6.4Hz,1H),2.25-2.15(m,J＝6.7Hz,1H),2.10(dt,J＝12.9,6.4Hz,1H),2.01-1.91(m,2H),1.89-1.55(m,10H),0.87(dd,J＝25.0,6.7Hz,6H).ESI-MS m/z 523.28[M+H] +.
实施例37:化合物37的合成
Figure PCTCN2020081481-appb-000057
用化合物8-1替换实施例12中的化合物12-1，合成方法参考化合物12的合成，得到化合物37。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),9.11(s,1H),8.53(d,J＝9.3Hz,1H),7.80(d,J＝9.0Hz,1H),7.67(d,J＝7.7Hz,1H),7.39(d,J＝7.9Hz,1H),7.36(s,1H),7.29-7.12(m,7H),6.55(t,J＝4.4Hz,1H),5.04(dt,J＝9.3,7.7Hz,1H),4.36(dt,J＝8.8,6.4Hz,1H),3.25(m,1H),3.15(m,1H),3.11-3.01(m,2H),2.41(m,1H),2.18(dt,J＝12.8,6.3Hz,1H),1.87(dt,J＝12.9,6.4Hz,1H),1.82-1.68(m,2H).ESI-MS m/z 446.19[M+H] +.
实施例38:化合物38的合成
Figure PCTCN2020081481-appb-000058
用化合物38-1替换实施例37中的化合物5-1，合成方法参考化合物12的合成，得到化合物38。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),8.56(d,J＝9.3Hz,1H),7.77(d,J＝9.0Hz,1H),7.68(d,J＝7.8Hz,1H),7.37(d,J＝8.6Hz,2H),7.30(dd,J＝8.2,7.3Hz,1H),7.27-7.18(m,6H),6.55(t,J＝4.4Hz,1H),4.97(dt,J＝9.3,7.8Hz,1H),4.60(dt,J＝8.8,6.4Hz,1H),3.94(s,3H),3.33(m,1H),3.16(m,1H),3.10(dd,J＝13.9,7.7Hz,1H),3.00(dd,J＝14.1,7.7Hz,1H),2.37(m,1H),2.13(dt,J＝12.9,6.4Hz,1H),1.88(dt,J＝12.9,6.4Hz,1H), 1.82-1.69(m,2H).ESI-MS m/z 460.21[M+H] +.
实施例39:化合物39的合成
Figure PCTCN2020081481-appb-000059
用化合物39-1替换实施例37中的化合物5-1，合成方法参考化合物12的合成，得到化合物39。
1H NMR(600MHz,Acetone-d6)δ9.30(s,1H),9.14(s,1H),8.53(d,J＝9.3Hz,1H),7.86(s,1H),7.82(d,J＝8.4Hz,1H),7.74(d,J＝8.8Hz,1H),7.52(s,1H),7.46(d,J＝8.4Hz,1H),7.27-7.18(m,5H),6.55(t,J＝4.4Hz,1H),4.91(dt,J＝9.3,7.7Hz,1H),4.53(dt,J＝9.0,6.3Hz,1H),3.37(m,1H),3.22(m,1H),3.09(dd,J＝14.0,7.8Hz,1H),3.00(dd,J＝13.9,7.7Hz,1H),2.44(m,1H),2.17(dt,J＝12.9,6.4Hz,1H),1.97(dt,J＝12.9,6.4Hz,1H),1.84(m,1H),1.76(m,1H).ESI-MS m/z 514.18[M+H] +.
实施例40:化合物40的合成
Figure PCTCN2020081481-appb-000060
用化合物13-1替换实施例37中的化合物5-1，合成方法参考化合物12的合成，得到化合物40。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),9.18(s,1H),8.51(d,J＝9.3Hz,1H),7.80(d,J＝8.8Hz,1H),7.51(d,J＝8.4Hz,1H),7.33(s,1H),7.30(s,1H),7.28-7.18(m,5H),6.80(d,J＝8.4Hz,1H),6.55(t,J＝4.4Hz,1H),5.05(dt,J＝9.3,7.8Hz,1H),4.34(dt,J＝9.0,6.3Hz,1H),3.84(s,3H),3.25(m,1H),3.19-3.11(m,1H),3.11-3.07(m,1H),3.00(dd,J＝14.1,7.7Hz,1H),2.41(m,1H),2.18(dt,J＝12.9,6.4Hz,1H),1.86(dt,J＝12.9,6.4Hz,1H),1.82-1.68(m,2H).ESI-MS m/z 476.21[M+H] +.
实施例41:化合物41的合成
Figure PCTCN2020081481-appb-000061
用化合物20-1替换实施例37中的化合物5-1，合成方法参考化合物37的合成，得到化合物41。
1H NMR(600MHz,Acetone-d6)δ9.30(s,1H),9.15(s,1H),8.53(d,J＝9.3Hz,1H),7.80(d,J＝8.8Hz,1H),7.61(s,1H),7.39(d,J＝8.4Hz,1H),7.32-7.07(m,7H),6.55(t,J＝4.4Hz,1H),5.06(dt,J＝9.3,7.8Hz,1H),4.48(dt,J＝8.8,6.4Hz,1H),3.36(m,1H),3.22(m,1H),3.09(dd,J＝14.1,7.7Hz,1H),3.00(dd,J＝13.9,7.7Hz,1H),2.43(m,1H),2.14(dt,J＝12.9,6.4Hz,1H),1.99(dt,J＝12.9,6.3Hz,1H),1.85-1.71(m,2H).ESI-MS m/z 480.16[M+H] +.
实施例42:化合物42的合成
Figure PCTCN2020081481-appb-000062
用化合物42-1替换实施例37中的化合物5-1，合成方法参考化合物37的合成，得到化合物42。
1H NMR(600MHz,Acetone-d6)δ9.30(s,1H),9.13(s,1H),8.61(d,J＝9.3Hz,1H),7.83(d,J＝4.9Hz,1H),7.77(d,J＝9.0Hz,1H),7.33(d,J＝7.8Hz,1H),7.29-7.19(m,4H),7.16-7.05(m,3H),6.55(t,J＝4.4Hz,1H),5.01(dt,J＝9.3,7.7Hz,1H),4.49(dt,J＝9.0,6.4Hz,1H),3.33(m,1H),3.21-3.00(m,3H),2.33(m,1H),2.11(dt,J＝12.9,6.4Hz,1H),1.99(dt,J＝12.9,6.3Hz,1H),1.84-1.71(m,2H).ESI-MS m/z 464.19[M+H] +.
实施例43:化合物43的合成
Figure PCTCN2020081481-appb-000063
用化合物43-1替换实施例37中的化合物5-1，合成方法参考化合物37的合成，得到化合物43。
1H NMR(600MHz,Acetone-d6)δ9.77(s,1H),9.21(s,1H),8.61(d,J＝9.3Hz,1H),7.77(d,J＝9.0Hz,1H),7.59(d,J＝7.9Hz,1H),7.39(s,1H),7.32(td,J＝7.9,4.9Hz,1H),7.29-7.18(m,5H),7.01(t,J＝8.0Hz,1H),6.55(t,J＝4.4Hz,1H),5.07(dt,J＝9.3,7.7Hz,1H),4.38(dt,J＝8.8,6.4Hz,1H), 3.37(m,1H),3.22(m,1H),3.10(dd,J＝14.0,7.8Hz,1H),3.00(dd,J＝13.9,7.7Hz,1H),2.44(m,1H),2.20(dt,J＝12.8,6.3Hz,1H),1.93(dt,J＝12.9,6.4Hz,1H),1.85-1.70(m,2H).ESI-MS m/z 464.19[M+H] +.
实施例44:化合物44的合成
Figure PCTCN2020081481-appb-000064
用化合物44-1替换实施例37中的化合物5-1，合成方法参考化合物37的合成，得到化合物44。
1H NMR(600MHz,Acetone-d6)δ9.76(s,1H),9.21(s,1H),8.58(d,J＝9.3Hz,1H),7.74(d,J＝8.8Hz,1H),7.44-7.36(m,2H),7.28-7.18(m,5H),6.90(t,J＝8.1Hz,1H),6.55(t,J＝4.4Hz,1H),5.06(dt,J＝9.3,7.7Hz,1H),4.41(dt,J＝9.0,6.3Hz,1H),3.37(m,1H),3.22(m,1H),3.10(dd,J＝13.9,7.7Hz,1H),3.00(dd,J＝14.1,7.7Hz,1H),2.44(m,1H),2.19(dt,J＝12.9,6.4Hz,1H),1.92(dt,J＝12.8,6.3Hz,1H),1.85-1.70(m,2H).ESI-MS m/z 482.18[M+H] +.
实施例45:化合物45的合成
Figure PCTCN2020081481-appb-000065
用化合物45-1替换实施例37中的化合物5-1，合成方法参考化合物37的合成，得到化合物45。
1H NMR(600MHz,Acetone-d6)δ9.30(s,1H),9.11(s,1H),8.51(d,J＝9.3Hz,1H),7.82(d,J＝9.0Hz,1H),7.57(d,J＝7.9Hz,1H),7.50(dd,J＝8.4,4.9Hz,1H),7.36(s,1H),7.29-7.18(m,3H),7.13(dd,J＝6.1,1.1Hz,2H),7.03(t,J＝8.2Hz,1H),6.55(t,J＝4.4Hz,1H),5.06(dt,J＝9.3,7.8Hz,1H),4.48(dt,J＝9.0,6.4Hz,1H),3.36(m,1H),3.22(m,1H),3.09(dd,J＝14.1,7.7Hz,1H),3.00(dd,J＝13.9,7.7Hz,1H),2.44(m,1H),2.14(dt,J＝12.9,6.3Hz,1H),1.99(dt,J＝12.8,6.3Hz,1H),1.85-1.70(m,2H).ESI-MS m/z 464.19[M+H] +.
实施例46:化合物46的合成
Figure PCTCN2020081481-appb-000066
用化合物46-1替换实施例37中的化合物5-1，合成方法参考化合物37的合成，得到化合物46。
1H NMR(600MHz,Acetone-d6)δ9.30(s,1H),9.23(s,1H),8.51(d,J＝9.3Hz,1H),7.93(dd,J＝8.4,4.9Hz,1H),7.82(d,J＝9.0Hz,1H),7.45(s,1H),7.29-7.22(m,3H),7.22-7.16(m,1H),7.16-7.06(m,3H),6.55(t,J＝4.4Hz,1H),5.07(dt,J＝9.3,7.8Hz,1H),4.48(dt,J＝9.0,6.4Hz,1H),3.36(m,1H),3.22(m,1H),3.10(dd,J＝13.9,7.7Hz,1H),3.00(dd,J＝14.1,7.7Hz,1H),2.44(m,1H),2.15(dt,J＝12.8,6.3Hz,1H),1.99(dt,J＝12.9,6.3Hz,1H),1.85-1.70(m,2H).ESI-MS m/z 464.19[M+H] +.
实施例47:化合物47的合成
Figure PCTCN2020081481-appb-000067
用化合物14-1替换实施例37中的化合物5-1，1-5替换8-1合成方法参考化合物37的合成，得到化合物47。
1H NMR(600MHz,Acetone-d6)δ9.30(s,1H),9.17(s,1H),8.57(d,J＝9.3Hz,1H),7.81(s,1H),7.74(d,J＝8.8Hz,1H),7.41(s,1H),7.31(s,1H),6.55(t,J＝4.4Hz,1H),4.51(dt,J＝8.8,6.4Hz,1H),4.43(dt,J＝9.3,6.9Hz,1H),3.36(m,1H),3.21(m,1H),2.43(m,1H),2.16(dt,J＝12.8,6.3Hz,1H),1.97(dt,J＝12.8,6.3Hz,1H),1.88-1.66(m,5H),1.64-1.44(m,5H),1.41-1.20(m,5H).ESI-MS m/z 520.16[M+H] +.
实施例48:化合物48的合成
Figure PCTCN2020081481-appb-000068
用化合物5-1替换实施例37中的化合物5-1，1-5替换8-1，合成方法参考化合物37的合成，得到化合物48。
1H NMR(600MHz,Acetone-d6)δ9.30(s,1H),9.11(s,1H),8.58(d,J＝9.2Hz,1H),7.80(d,J＝8.8Hz,1H),7.67(d,J＝7.6Hz,1H),7.44(s,1H),7.39(d,J＝7.9Hz,1H),7.25-7.13(m,2H),6.55(t,J＝4.4Hz,1H),4.48(m,2H),3.35(m,1H),3.20(m,1H),2.42(m,1H),2.15(dt,J＝12.9,6.4Hz,1H),2.02-1.89(m,2H),1.85-1.44(m,9H),1.39-1.20(m,5H).ESI-MS m/z 452.24[M+H] +.
实施例49:化合物49的合成
Figure PCTCN2020081481-appb-000069
用化合物38-1替换实施例47中的化合物14-1，合成方法参考化合物47的合成，得到化合物49。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),8.62(d,J＝9.3Hz,1H),7.76(d,J＝8.8Hz,1H),7.68(d,J＝7.8Hz,1H),7.37(d,J＝8.3Hz,1H),7.33-7.26(m,2H),7.20(t,J＝7.6Hz,1H),6.55(t,J＝4.4Hz,1H),4.33(m,2H),3.94(s,3H),3.24(m,1H),3.13(m,1H),2.39(m,1H),2.18(dt,J＝12.9,6.3Hz,1H),1.98(dt,J＝13.8,6.9Hz,1H),1.91-1.84(m,2H),1.84-1.74(m,2H),1.74-1.67(m,1H),1.67-1.44(m,7H),1.39-1.21(m,5H).ESI-MS m/z 466.26[M+H] +.
实施例50:化合物50的合成
Figure PCTCN2020081481-appb-000070
用化合物50-1替换实施例47中的化合物14-1，合成方法参考化合物47的合 成，得到化合物50。
1H NMR(600MHz,Acetone-d6)δ9.30(s,1H),9.15(s,1H),8.58(d,J＝9.3Hz,1H),7.79(d,J＝8.8Hz,1H),7.40(d,J＝8.9Hz,2H),7.27(s,1H),6.80(d,J＝8.4Hz,1H),6.55(t,J＝4.4Hz,1H),4.55(dt,J＝9.0,6.4Hz,1H),4.42(dt,J＝9.3,6.9Hz,1H),3.84(s,3H),3.35(m,1H),3.20(m,1H),2.46(m,1H),2.13(dt,J＝12.8,6.4Hz,1H),1.98(dt,J＝12.9,6.4Hz,1H),1.86-1.65(m,5H),1.64-1.53(m,2H),1.53-1.43(m,3H),1.40-1.20(m,5H).ESI-MS m/z 482.25[M+H] +.
实施例51:化合物51的合成
Figure PCTCN2020081481-appb-000071
用化合物42-1替换实施例47中的化合物14-1，合成方法参考化合物47的合成，得到化合物51。
1H NMR(600MHz,Acetone-d6)δ9.30(s,1H),9.13(s,1H),8.63(d,J＝9.3Hz,1H),7.80-7.71(m,2H),7.27(d,J＝7.8Hz,1H),7.21(td,J＝7.8,4.9Hz,1H),7.09(t,J＝7.8Hz,1H),6.55(t,J＝4.4Hz,1H),4.51(dt,J＝9.0,6.4Hz,1H),4.43(dt,J＝9.3,6.9Hz,1H),3.36(m,1H),3.21(m,1H),2.42(m,1H),2.16(dt,J＝12.9,6.4Hz,1H),2.00(dt,J＝12.9,6.3Hz,1H),1.86-1.66(m,5H),1.64-1.44(m,5H),1.41-1.20(m,5H).ESI-MS m/z 470.23[M+H] +.
实施例52:化合物52的合成
Figure PCTCN2020081481-appb-000072
用化合物45-1替换实施例47中的化合物14-1，合成方法参考化合物47的合成，得到化合物52。
1H NMR(600MHz,Acetone-d6)δ9.30(s,1H),9.11(s,1H),8.54(d,J＝9.2Hz,1H),7.79(d,J＝8.8Hz,1H),7.53(d,J＝7.9Hz,1H),7.47(dd,J＝8.4,4.9Hz,1H),7.37(s,1H),7.03(t,J＝8.2Hz,1H),6.55(t,J＝4.4Hz,1H), 4.52(dt,J＝9.0,6.4Hz,1H),4.45(dt,J＝9.3,6.9Hz,1H),3.35(m,1H),3.20(m,1H),2.43(m,1H),2.12(dt,J＝12.8,6.3Hz,1H),1.99(dt,J＝12.9,6.3Hz,1H),1.92-1.68(m,4H),1.68-1.44(m,7H),1.40-1.24(m,5H).ESI-MS m/z 470.23[M+H] +.
实施例53:化合物53的合成
Figure PCTCN2020081481-appb-000073
用化合物46-1替换实施例47中的化合物14-1，合成方法参考化合物47的合成，得到化合物53。
1H NMR(600MHz,Acetone-d6)δ9.30(s,1H),9.23(s,1H),8.54(d,J＝9.2Hz,1H),7.90(dd,J＝8.4,4.9Hz,1H),7.79(d,J＝8.8Hz,1H),7.49(s,1H),7.18-7.07(m,2H),6.55(t,J＝4.4Hz,1H),4.51(dt,J＝8.8,6.3Hz,1H),4.43(dt,J＝9.3,6.9Hz,1H),3.36(m,1H),3.21(m,1H),2.42(m,1H),2.16(dt,J＝12.9,6.4Hz,1H),1.99(dt,J＝12.8,6.3Hz,1H),1.86-1.66(m,5H),1.59(m,2H),1.55-1.50(m,2H),1.50-1.44(m,2H),1.41-1.20(m,5H).ESI-MS m/z 470.23[M+H] +.
实施例54:化合物54的合成
Figure PCTCN2020081481-appb-000074
用化合物43-1替换实施例47中的化合物14-1，合成方法参考化合物47的合成，得到化合物54。
1H NMR(600MHz,Acetone-d6)δ9.78(s,1H),9.21(s,1H),8.63(d,J＝9.3Hz,1H),7.74(d,J＝8.8Hz,1H),7.57(d,J＝7.9Hz,1H),7.47(s,1H),7.30(td,J＝7.9,5.0Hz,1H),7.00(t,J＝7.9Hz,1H),6.55(t,J＝4.4Hz,1H),4.47-4.35(m,2H),3.37(m,1H),3.22(m,1H),2.43(m,4.5Hz,1H),2.21(dt,J＝12.8,6.3Hz,1H),1.94(dt,J＝12.9,6.3Hz,1H),1.88-1.66(m,5H),1.64-1.44(m,5H),1.41-1.21(m,5H).ESI-MS m/z 470.23[M+H] +.
实施例55:化合物55的合成
Figure PCTCN2020081481-appb-000075
用化合物10-1替换实施例47中的化合物14-1，合成方法参考化合物47的合成，得到化合物55。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),8.50(d,J＝9.3Hz,1H),7.83-7.76(m,2H),7.64(dd,J＝9.8,7.7Hz,2H),7.39(t,J＝7.5Hz,1H),7.32(t,J＝7.4Hz,1H),6.55(t,J＝4.4Hz,1H),4.38(dt,J＝8.8,6.4Hz,1H),4.25(dt,J＝9.3,6.9Hz,1H),3.32(m,1H),3.20(m,1H),2.42(m,1H),2.16(dt,J＝12.9,6.4Hz,1H),1.98-1.65(m,6H),1.59(m,2H),1.57-1.44(m,3H),1.41-1.18(m,5H).ESI-MS m/z 453.23[M+H] +.
实施例56:化合物56的合成
Figure PCTCN2020081481-appb-000076
用化合物24-1替换实施例47中的化合物14-1，合成方法参考化合物47的合成，得到化合物56。
1H NMR(600MHz,Acetone-d6)δ9.30(s,1H),8.46(d,J＝9.3Hz,1H),8.30(s,1H),7.96(d,J＝7.8Hz,1H),7.83-7.77(m,2H),7.42(t,J＝7.6Hz,1H),7.35(t,J＝7.6Hz,1H),6.55(t,J＝4.4Hz,1H),4.48(dt,J＝8.8,6.4Hz,1H),4.29(dt,J＝9.3,6.9Hz,1H),3.32-3.16(m,2H),2.36(m,1H),2.17(dt,J＝12.9,6.4Hz,1H),1.96(m,2H),1.86-1.44(m,10H),1.41-1.17(m,6H).ESI-MS m/z 469.20[M+H] +.
实施例57:化合物57的合成
Figure PCTCN2020081481-appb-000077
用化合物57-1替换实施例47中的化合物14-1，合成方法参考化合物47的合成，得到化合物57。
1H NMR(600MHz,Acetone-d6)δ9.30(s,1H),8.63(d,J＝9.3Hz,1H),7.83-7.73(m,2H),7.65-7.57(m,1H),7.29-7.21(m,2H),6.55(t,J＝4.4Hz,1H),4.56-4.47(m,2H),3.36(m,1H),3.21(m,1H),2.42(m,1H),2.15(dt,J＝12.8,6.3Hz,1H),1.98(dt,J＝12.8,6.3Hz,1H),1.85-1.66(m,5H),1.63-1.45(m,6H),1.42-1.21(m,6H).ESI-MS m/z 453.24[M+H] +.
实施例58:化合物58的合成
Figure PCTCN2020081481-appb-000078
用化合物11-1替换实施例47中的化合物14-1，合成方法参考化合物47的合成，得到化合物58。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),8.57(d,J＝9.3Hz,1H),8.35-8.26(m,2H),8.15(d,J＝8.1Hz,1H),7.93(d,J＝7.5Hz,1H),7.85(dd,J＝8.2,7.4Hz,1H),7.71(d,J＝8.8Hz,1H),7.59(t,J＝7.4Hz,1H),6.55(t,J＝4.4Hz,1H),4.45-4.35(m,2H),3.27(m,1H),3.12(m,1H),2.40(m,1H),2.10(dt,J＝12.8,6.3Hz,1H),2.00-1.89(m,2H),1.84-1.65(m,3H),1.65-1.43(m,6H),1.39-1.19(m,5H).ESI-MS m/z 464.24[M+H] +.
实施例59:化合物59的合成
Figure PCTCN2020081481-appb-000079
用化合物59-1替换实施例47中的化合物14-1，合成方法参考化合物47的合成，得到化合物59。
1H NMR(600MHz,Acetone-d6)δ9.36(s,1H),9.21(s,1H),8.64(d,J＝9.3Hz,1H),7.99(dd,J＝7.8,3.7Hz,2H),7.86(t,J＝7.6Hz,1H),7.75(d,J＝9.0Hz,1H),7.61-7.54(m,1H),6.55(t,J＝4.4Hz,1H),4.43(dt,J＝9.3,6.9Hz,1H),4.37(dt,J＝8.8,6.4Hz,1H),3.23(m,1H),3.02(m,1H),2.36(m,1H),2.09(dt,J＝12.7,6.3Hz,1H),1.99-1.89(m,2H),1.83-1.44(m,10H),1.40-1.19(m,6H).ESI-MS m/z 465.24[M+H] +.
实施例60:化合物60的合成
Figure PCTCN2020081481-appb-000080
用化合物60-1替换实施例5中的化合物1-8，合成方法参考化合物9的合成，得到化合物60。
1H NMR(600MHz,Acetone-d6)δ9.30(s,1H),9.12(s,1H),8.79(d,J＝9.1Hz,1H),7.71-7.60(m,3H),7.42-7.35(m,2H),7.23(t,J＝7.6Hz,1H),7.20-7.13(m,1H),6.55(t,J＝4.4Hz,1H),4.50(dt,J＝8.8,6.4Hz,1H),4.38(dt,J＝9.3,6.8Hz,1H),4.18(dd,J＝9.1,5.2Hz,1H),3.30(m,1H),3.15(m,1H),2.39(m,1H),2.11(dt,J＝12.8,6.3Hz,1H),1.97(dt,J＝12.9,6.3Hz,1H),1.92-1.65(m,5H),1.62-1.52(m,1H),1.52-1.31(m,9H),1.23-1.08(m,4H),0.89-0.80(m,2H).ESI-MS m/z 549.29[M+H] +.
实施例61:化合物61的合成
Figure PCTCN2020081481-appb-000081
用化合物61-1替换实施例47中的化合物14-1，合成方法参考化合物47的合成，得到化合物61。
1H NMR(600MHz,Acetone-d6)δ9.21(s,1H),8.48(d,J＝9.3Hz,1H),7.66(d,J＝8.8Hz,1H),7.54(d,J＝8.4Hz,1H),7.42(s,1H),6.88(d,J＝8.4Hz,1H),6.55(t,J＝4.4Hz,1H),6.05(d,J＝6.8Hz,2H),4.35(m,2H),3.32(m,1H),3.19(m,1H),2.40(m,1H),2.19(dt,J＝12.8,6.3Hz,1H),1.93-1.67(m,6H),1.59(m,2H),1.57-1.44(m,3H),1.41-1.20(m,6H).ESI-MS m/z 457.22[M+H] +.
实施例62:化合物62的合成
Figure PCTCN2020081481-appb-000082
用化合物6-1替换实施例47中的化合物14-1，合成方法参考化合物47的合成，得到化合物62。
1H NMR(600MHz,Acetone-d6)δ11.14(d,J＝8.4Hz,1H),9.41(s,1H),8.28-8.23(m,1H),7.78(dd,J＝12.5,8.8Hz,1H),7.58(d,J＝1.8Hz,1H),7.47(d,J＝8.8Hz,1H),7.37-7.33(m,2H),7.23(d,J＝7.7Hz,2H),7.16(dd,J＝6.3,1.9Hz,4H),5.44(dd,J＝70.6,8.0Hz,1H),5.06(dd,J＝7.1,4.5Hz,1H),4.51(m,1H),4.13-3.99(m,1H),3.32(d,J＝2.0Hz,1H),3.20(m,2H),2.44-2.34(m,1H),2.33-2.25(m,1H),1.79-1.55(m,2H).ESI-MS m/z 413.17[M+H] +.
实施例63:化合物63的合成
Figure PCTCN2020081481-appb-000083
用化合物63-1替换实施例47中的化合物14-1，合成方法参考化合物47的合成，得到化合物63。
1H NMR(600MHz,Acetone-d6)δ9.42(s,1H),8.87(d,J＝12.0Hz,1H),8.75(d,J＝6.0Hz,1H),8.63(d,J＝2.7Hz,1H),8.24(d,J＝8.1Hz,1H),7.98-7.94(m,1H),7.37(d,J＝7.3Hz,2H),7.30(dd,J＝10.4,4.7Hz,2H),7.22(m,1H),5.01(m,1H),4.32-4.27(m,1H),3.38-3.34(m,1H),3.31-3.27(m,1H),3.19(dd,J＝13.9,8.9Hz,1H),2.51-2.40(m,1H),2.39-2.33(m,1H),1.97-1.88(m,1H),1.82(m,1H),1.39(s,1H),1.31(d,J＝2.5Hz,2H).ESI-MS m/z 427.16[M+H] +.
实施例64:化合物64的合成
Figure PCTCN2020081481-appb-000084
用化合物64-1替换实施例12中的酸5-1，化合物8-1替换实施例1中12-1，合成方法参考化合物12的合成，得到化合物64。
1H NMR(600MHz,Acetone-d6)δ9.43(s,1H),8.59(d,J＝6.8Hz,1H),8.18(dd,J＝15.6,1.8Hz,1H),8.08-7.99(m,1H),7.92-7.82(m,2H),7.53(t,J＝8.1Hz,1H),7.38(d,J＝7.3Hz,2H),7.28(t,J＝7.5Hz,2H),7.19(t,J＝7.3Hz,1H),7.13(s,1H),6.97-6.90(m,1H),5.07(m,1H),4.37(m,1H),3.37-3.33(m,1H),3.29-3.20(m,3H),2.52-2.24(m,2H),2.05-1.98(m,1H),1.87-1.62(m,2H).ESI-MS m/z 448.17[M+H] +.
实施例65:化合物65的合成
Figure PCTCN2020081481-appb-000085
用化合物65-1替换实施例12中的酸5-1，化合物8-1替换实施例1中12-1，合成方法参考化合物12的合成，得到化合物65。
1H NMR(600MHz,Acetone-d6)δ9.22(s,1H),8.36(d,J＝6.3Hz,1H),7.32(d,J＝2.0Hz,1H),7.23(s,5H),7.02(d,J＝8.1Hz,1H),6.83(d,J＝8.4Hz,1H),6.55(s,1H),5.07(m,1H),4.27-4.21(m,6H),3.31-3.24(m,2H),3.20(dd,J＝14.4,6.7Hz,2H),2.35-2.28(m,2H),1.90(dd,J＝10.2,6.4Hz,1H),1.80(m,2H).ESI-MS m/z 466.18[M+H] +.
实施例66:化合物66的合成
Figure PCTCN2020081481-appb-000086
用化合物66-1替换实施例12中的酸5-1，化合物8-1替换实施例1中12-1，合成方法参考化合物12的合成，得到化合物66。
1H NMR(600MHz,Acetone-d6)δ11.14(d,J＝8.8Hz,1H),9.41(s,1H),8.28-8.23(m,1H),7.78(m,1H),7.58(d,J＝1.8Hz,1H),7.47(d,J＝8.8Hz,1H),7.37-7.33(m,2H),7.23(d,J＝7.7Hz,2H),7.16(dd,J＝6.3,1.9Hz,4H),5.44m,1H),5.06(dd,J＝7.1,4.5Hz,1H),4.51(m,1H),4.13-3.99(m,1H),3.32(d,J＝2.0Hz,1H),3.20(m,2H),2.44-2.34(m,1H),2.33-2.25(m,1H),1.79-1.55(m,2H).ESI-MS m/z 466.18[M+H] +.
实施例67:化合物67的合成
Figure PCTCN2020081481-appb-000087
用化合物67-1替换实施例12中的酸5-1，化合物8-1替换实施例1中12-1，合成方法参考化合物12的合成，得到化合物67。
1H NMR(600MHz,Acetone-d6)δ10.53(s,1H),9.39(s,1H), 8.19-8.16(m,1H),7.73(d,J＝8.0Hz,1H),7.66(dd,J＝8.5,1.7Hz,1H),7.43(d,J＝8.5Hz,1H),7.40-7.38(m,1H),7.37-7.33(m,2H),7.26(m,2H),7.19-7.15(m,1H),6.96(s,1H),6.54(m,1H),5.01(dt,J＝8.2,4.0Hz,1H),4.31-4.26(m,1H),3.31(dd,J＝8.2,5.6Hz,1H),3.26-3.18(m,3H),2.45-2.36(m,1H),2.32-2.21(m,1H),1.98-1.95(m,1H),1.81-1.68(m,2H).ESI-MS m/z 447.19[M+H] +.
实施例68:化合物68的合成
Figure PCTCN2020081481-appb-000088
用化合物68-1替换实施例12中的酸5-1，化合物8-1替换实施例1中12-1，合成方法参考化合物12的合成，得到化合物68。
1H NMR(600MHz,Acetone-d6)δ9.40(s,1H),8.79(s,1H),8.53(d,J＝6.2Hz,1H),8.27(d,J＝4.9Hz,1H),8.04(d,J＝7.3Hz,1H),7.58-7.52(m,1H),7.47-7.40(m,1H),7.32(t,J＝6.4Hz,2H),7.28-7.22(m,2H),7.18(t,J＝7.2Hz,1H),6.91(s,1H),5.03-4.93(m,1H),4.44(m,1H),3.32(t,J＝6.9Hz,1H),3.27-3.23(m,1H),2.45-2.26(m,2H),1.99-1.94(m,1H),1.80-1.75(m,1H),1.37(s,1H),1.29(d,J＝3.3Hz,2H).ESI-MS m/z 526.11[M+H] +.
实施例69:化合物69的合成
Figure PCTCN2020081481-appb-000089
用化合物24-1替换实施例12中的酸5-1，化合物8-1替换实施例1中12-1，合成方法参考化合物12的合成，得到化合物69。
1H NMR(600MHz,Acetone-d6)δ11.14(d,J＝8.4Hz,1H),9.41(s,1H),8.28-8.23(m,1H),7.78(dd,J＝12.5,8.8Hz,1H),7.58(d,J＝1.8Hz,1H),7.47(d,J＝8.8Hz,1H),7.37-7.33(m,2H),7.23(d,J＝7.7Hz,2H),7.16(dd,J＝6.3,1.9Hz,4H),5.44(m,1H),5.06(dd,J＝7.1,4.5Hz,1H),4.51(m,1H),4.13-3.99(m,1H),3.32(d,J＝2.0Hz,1H),3.20(m,2H),2.44-2.34(m,1H),2.33-2.25(m,1H),1.79-1.55(m,2H).ESI-MS m/z 464.15[M+H] +.
实施例70:化合物70的合成
Figure PCTCN2020081481-appb-000090
用化合物10-1替换实施例12中的酸5-1，化合物8-1替换实施例1中12-1，合成方法参考化合物12的合成，得到化合物70。
1H NMR(600MHz,Acetone-d6)δ9.43(s,1H),8.64(d,J＝6.8Hz,1H),8.11(d,J＝8.0Hz,1H),7.71(d,J＝7.5Hz,1H),7.56-7.50(m,1H),7.49-7.41(m,2H),7.37(dd,J＝9.2,2.3Hz,2H),7.32-7.22(m,3H),7.19(d,J＝7.5Hz,1H),7.12(s,1H),5.10-5.01(m,1H),4.58-4.32(m,1H),3.38(m,1H),3.25(dd,J＝9.0,2.5Hz,3H),2.53-2.27(m,2H),2.04(m,1H),1.86-1.62(m,2H).ESI-MS m/z 448.17[M+H] +.
实施例71:化合物71的合成
Figure PCTCN2020081481-appb-000091
用化合物59-1替换实施例12中的酸5-1，化合物8-1替换实施例1中12-1，合成方法参考化合物12的合成，得到化合物71。
1H NMR(600MHz,Acetone-d6)δ9.47(s,1H),8.69(d,J＝8.0Hz,1H),8.15(m,2H),7.95(m,2H),7.80(d,J＝8.0Hz,1H),7.34(d,J＝7.3Hz,2H),7.25(t,J＝7.3Hz,2H),7.18(t,J＝7.3Hz,1H),6.83(s,1H),5.03-4.95(m,1H),3.99(dd,J＝7.3,4.3Hz,1H),3.50(m,2H),3.31-3.20(m,3H),2.39-2.28(m,2H),1.95-1.87(m,1H),1.78-1.68(m,1H),1.62-1.51(m,1H).ESI-MS m/z 460.18[M+H] +.
实施例72:化合物72的合成
Figure PCTCN2020081481-appb-000092
用化合物72-1替换实施例1中的酸1-11，化合物8-1替换实施例1中1-5，合成方法参考化合物1的合成，得到化合物72。
1H NMR(600MHz,Acetone-d6)δ9.30(s,1H),8.63(d,J＝8.5Hz,1H),8.33(d,J＝6.2Hz,1H),8.06(d,J＝7.5Hz,1H),8.02(d,J＝8.5Hz,1H),7.80(m,1H),7.75 (dd,J＝11.0,4.0Hz,1H),7.39-7.27(m,5H),7.25(d,J＝7.1Hz,1H),6.56(s,1H),5.12(q,J＝7.1Hz,1H),4.32(m,1H),3.31(dd,J＝12.8,6.2Hz,3H),3.02(s,3H),2.40-2.30(m,2H),1.99-1.93(m,1H),1.88-1.75(m,2H).ESI-MS m/z 474.21[M+H] +.
实施例73:化合物73的合成
Figure PCTCN2020081481-appb-000093
用化合物11-1替换实施例1中的酸1-11，化合物8-1替换实施例1中1-5，合成方法参考化合物1的合成，得到化合物73。
1H NMR(600MHz,Acetone-d6)δ9.22(s,1H),8.84(d,J＝8.5Hz,1H),8.28(d,J＝8.5Hz,1H),8.22(dd,J＝10.1,6.0Hz,1H),8.11(m,2H),7.86(d,J＝8.1Hz,1H),7.77(dd,J＝11.2,4.1Hz,1H),7.62(m,1H),7.36-7.27(m,4H),7.24(t,J＝7.2Hz,1H),5.08(m,1H),4.33-4.28(m,1H),3.35-3.29(m,2H),3.25(t,J＝6.8Hz,2H),2.38-2.30(m,2H),1.93-1.84(m,2H),1.79-1.71(m,2H).ESI-MS m/z 459.19[M+H] +.
实施例74:化合物74的合成
Figure PCTCN2020081481-appb-000094
用化合物74-1替换实施例1中的酸1-11，化合物8-1替换实施例1中1-5，合成方法参考化合物1的合成，得到化合物74。
1H NMR(600MHz,Acetone-d6)δ9.46(s,1H),8.91(dd,J＝7.9,4.6Hz,1H),8.71(d,J＝6.6Hz,1H),8.44-8.39(m,1H),8.24(m,1H),8.17(t,J＝7.9Hz,1H),7.98(dd,J＝14.5,7.3Hz,1H),7.90(m,1H),7.42-7.38(m,2H),7.30-7.25(m,2H),7.20(dd,J＝10.4,4.4Hz,1H),7.02(m,1H),5.16-5.07(m,1H),4.62-4.32(m,1H),3.42-3.37(m,1H),3.30(s,2H),2.53-2.30(m,2H),1.99(m,1H),1.88-1.62(m,2H).ESI-MS m/z 527.18[M+H] +.
实施例75:化合物75的合成
Figure PCTCN2020081481-appb-000095
用化合物25-1替换实施例1中的酸1-11，化合物8-1替换实施例1中1-5，合成方法参考化合物1的合成，得到化合物75。
1H NMR(600MHz,Acetone-d6)δ11.14(d,J＝8.4Hz,1H),9.41(s,1H),8.28-8.23(m,1H),7.78(dd,J＝12.5,8.8Hz,1H),7.58(d,J＝1.8Hz,1H),7.47(d,J＝8.8Hz,1H),7.37-7.33(m,2H),7.23(d,J＝7.7Hz,2H),7.16(dd,J＝6.3,1.9Hz,4H),5.44(m,1H),5.06(dd,J＝7.1,4.5Hz,1H),4.51(m,1H),4.13-3.99(m,1H),3.32(d,J＝2.0Hz,1H),3.20(m,2H),2.44-2.34(m,1H),2.33-2.25(m,1H),1.79-1.55(m,2H).ESI-MS m/z 537.10[M+H] +.
实施例76:化合物76的合成
Figure PCTCN2020081481-appb-000096
用化合物2-1替换实施例1中的酸1-11，化合物8-1替换实施例1中1-5，合成方法参考化合物1的合成，得到化合物76。
1H NMR(600MHz,Acetone-d6)δ9.24(s,1H),8.55(d,J＝6.0Hz,1H),7.29-7.26(m,2H),7.22(m,5H),7.10(m,1H),6.99(d,J＝2.6Hz,1H),6.95(s,1H),6.72(d,J＝8.6Hz,1H),6.58(s,1H),5.01(dd,J＝14.9,6.9Hz,1H),4.91-4.85(m,2H),4.25-4.20(m,1H),3.32-3.26(m,2H),3.18(m,2H),2.34-2.29(m,2H),1.94-1.87(m,1H),1.82-1.77(m,1H).ESI-MS m/z 496.15[M+H] +.
实施例77:化合物77的合成
Figure PCTCN2020081481-appb-000097
用化合物65-1替换实施例1中的酸1-11，化合物8-1替换实施例1中1-5，合成方法参考化合物1的合成，得到化合物77。
1H NMR(600MHz,Acetone-d6)δ9.72(s,1H),8.05(s,1H),7.65-7.46(m,3H),7.21-7.09(m,3H),5.99(s,1H),5.78(s,1H),5.08(s,1H), 4.91(m,2H),4.29(m,4H),3.64(s,1H),3.54(s,1H),3.29(s,1H),3.04(s,1H),2.81(s,1H),2.73(s,1H),2.22(s,1H),2.02(s,1H),1.91(s,1H),0.96(s,6H).ESI-MS m/z 565.26[M+H] +.
实施例78:化合物78的合成
Figure PCTCN2020081481-appb-000098
用化合物13-1替换实施例1中的酸1-11，合成方法参考化合物1的合成，得到化合物78。
1H NMR(600MHz,Acetone-d6)δ9.69(s,1H),8.57(s,1H),8.39(s,1H),7.56(s,1H),7.42(s,1H),7.14(s,1H),6.89(s,1H),6.77(s,1H),5.95(s,1H),5.43(s,1H),5.16(s,1H),4.92(s,1H),4.49(s,1H),3.80(s,3H),3.64(s,1H),3.53(s,1H),2.85(s,1H),2.72(s,1H),2.22(s,1H),2.02(s,1H),1.91(s,1H),1.75(s,1H),1.60(s,1H),1.54-1.36(m,7H),1.29(s,1H),0.96(s,6H).ESI-MS m/z 582.32[M+H] +.
实施例79:化合物79的合成
Figure PCTCN2020081481-appb-000099
用化合物14-1替换实施例1中的酸1-11，合成方法参考化合物1的合成，得到化合物79。
1H NMR(600MHz,Acetone-d6)δ9.72(s,1H),8.59(s,1H),7.41(s,1H),7.41-7.28(m,3H),7.10(s,1H),6.67(s,1H),6.04(s,1H),4.99(s,1H),4.78(s,1H),4.50(s,1H),3.65(s,1H),3.53(s,1H),2.73(s,1H),2.56(s,1H),2.21(s,1H),2.02(s,1H),1.91(s,1H),1.76(s,2H),1.60(s,1H),1.51(m,3H),1.48-1.41(m,4H),1.38(s,1H),0.96(s,6H).ESI-MS m/z 620.23[M+H] +.
实施例80:化合物80的合成
Figure PCTCN2020081481-appb-000100
用化合物80-1替换实施例1中的酸1-11，合成方法参考化合物1的合成，得 到化合物80。
1H NMR(600MHz,Acetone-d6)δ9.72(s,1H),7.91(s,2H),7.59(s,2H),7.51(s,1H),7.32(m,1H),6.99(s,1H),6.08(s,1H),6.01(s,1H),5.53(s,1H),4.91(m,2H),4.59(s,1H),3.65(s,1H),3.54(s,1H),2.73(m,2H),2.22(s,1H),2.02(s,1H),1.92(s,1H),1.76(s,1H),1.58(s,1H),1.55-1.41(m,5H),1.28(s,1H),0.96(s,6H).ESI-MS m/z 539.31[M+H] +.
实施例81:化合物81的合成
Figure PCTCN2020081481-appb-000101
用化合物81-1替换实施例12中的化合物12-1，合成方法参考化合物12的合成，得到化合物81。
1H NMR(600MHz,Acetone-d6)δ9.30(s,1H),9.11(s,1H),8.57(d,J＝9.3Hz,1H),7.80(d,J＝9.0Hz,1H),7.74(s,1H),7.66(d,J＝7.6Hz,1H),7.39(d,J＝7.8Hz,1H),7.30(td,J＝7.9,4.9Hz,1H),7.25-7.13(m,2H),6.98(td,J＝8.1,2.9Hz,3H),6.55(t,J＝4.4Hz,1H),5.07(dt,J＝9.3,7.7Hz,1H),4.46(dt,J＝8.8,6.3Hz,1H),3.33(m,1H),3.16(m,1H),3.03(dd,J＝14.0,7.8Hz,1H),2.96(dd,J＝13.9,7.7Hz,1H),2.28(m,1H),2.11(dt,J＝12.9,6.4Hz,1H),1.95(dt,J＝12.9,6.3Hz,1H),1.84-1.69(m,2H).ESI-MS m/z 464.19[M+H]+.
实施例82:化合物82的合成
Figure PCTCN2020081481-appb-000102
用化合物4-1替换实施例12中的化合物12-1，合成方法参考化合物12的合成，得到化合物82。
1H NMR(500MHz,Chloroform)δ11.66(s,1H),9.72(s,1H),7.98(dt,J＝14.9,3.1Hz,1H),7.60(dd,J＝14.9,3.2Hz,1H),7.31(d,J＝3.0Hz,1H),7.29-6.93(m,7H),6.44(s,1H),5.20(dd,J＝25.8,13.3Hz,1H),5.04(t,J＝10.4Hz,1H),3.76-3.48(m,2H),3.29(dd,J＝24.7, 10.3Hz,1H),3.04(dd,J＝24.8,10.4Hz,1H),2.59(ddd,J＝23.1,15.0,9.2Hz,1H),2.32-2.14(m,1H),2.07-1.88(m,3H).ESI-MS m/z 465.19[M+H] +.
实施例83:化合物83的合成
Figure PCTCN2020081481-appb-000103
用化合物83-1替换实施例81中的化合物5-1，合成方法参考化合物81的合成，得到化合物83。
1H NMR(500MHz,Chloroform)δ10.96(s,1H),9.72(s,1H),7.86(s,1H),7.43(d,J＝5.0Hz,1H),7.39-7.26(m,2H),7.14-6.95(m,5H),5.04(t,J＝5.4Hz,1H),4.84(q,J＝6.0Hz,1H),3.69(dt,J＝12.7,6.5Hz,1H),3.56(dt,J＝12.7,6.5Hz,1H),3.29(dd,J＝12.4,5.3Hz,1H),3.04(dd,J＝12.4,5.3Hz,1H),2.61(tt,J＝9.1,6.5Hz,1H),2.23(ddt,J＝12.9,9.1,6.4Hz,1H),2.02(t,J＝6.2Hz,2H),1.99-1.88(m,1H).ESI-MS m/z 501.17[M+H] +.
实施例84:化合物84的合成
Figure PCTCN2020081481-appb-000104
用化合物84-1替换实施例47中的化合物14-1，合成方法参考化合物47的合成，得到化合物84。
1H NMR(500MHz,Chloroform)δ11.97(s,1H),9.72(s,1H),7.50(dd,J＝14.9,3.2Hz,1H),7.11(s,1H),7.03(t,J＝15.0Hz,1H),6.85(dd,J＝15.0,3.1Hz,1H),6.45(s,2H),5.09(dd,J＝25.7,13.2Hz,1H),4.46(t,J＝11.8Hz,1H),3.74-3.48(m,2H),2.66-2.53(m,4H),2.21(ddd,J＝25.3,16.7,12.5Hz,1H),2.07-1.88(m,4H),1.86-1.63(m,7H),1.31(p,J＝11.6Hz,2H),1.17-0.97(m,3H).ESI-MS m/z 467.26[M+H] +.
实施例85:化合物85的合成
Figure PCTCN2020081481-appb-000105
用化合物85-1替换实施例12中的化合物12-1，合成方法参考化合物12的合成，得到化合物85。
1H NMR(500MHz,Chloroform)δ11.30(s,1H),9.72(s,1H),8.78(s,1H),7.98(dt,J＝14.9,3.1Hz,1H),7.60(dtd,J＝14.7,8.0,3.2Hz,2H),7.29-6.93(m,6H),6.35(s,1H),6.02(s,1H),5.66(s,1H),5.36(dd,J＝23.9,11.7Hz,1H),4.96(t,J＝10.8Hz,1H),3.72-3.47(m,2H),3.29(dd,J＝24.7,10.8Hz,1H),3.04(dd,J＝24.7,10.8Hz,1H),2.88(tt,J＝18.3,12.5Hz,1H),2.23(ddt,J＝25.5,18.3,12.8Hz,1H),2.07-1.82(m,3H).ESI-MS m/z 465.19[M+H] +.
实施例86:化合物86的合成
Figure PCTCN2020081481-appb-000106
用化合物57-1替换实施例81中的化合物5-1，合成方法参考化合物81的合成，得到化合物86。
1H NMR(500MHz,Chloroform)δ13.79(s,1H),9.71(s,1H),7.59(dt,J＝14.9,7.4Hz,2H),7.36-7.21(m,3H),7.07-6.94(m,3H),6.35(s,1H),6.15(s,1H),5.41(s,1H),5.15(dt,J＝12.4,10.3Hz,1H),4.87(t,J＝14.7Hz,1H),3.75-3.60(m,1H),3.60-3.45(m,1H),3.29(dd,J＝24.9,14.5Hz,1H),3.04(dd,J＝24.9,14.5Hz,1H),2.69(tt,J＝18.3,6.8Hz,1H),2.28-2.10(m,1H),2.06-1.89(m,3H).ESI-MS m/z 466.18[M+H] +.
实施例87:化合物87的合成
Figure PCTCN2020081481-appb-000107
用化合物10-1替换实施例81中的化合物5-1，合成方法参考化合物81的合成，得到化合物87。
1H NMR(500MHz,Chloroform)δ9.72(s,1H),8.04(s,1H),7.63-7.55(m,1H),7.50(dd,J＝14.3,3.6Hz,1H),7.36-7.15(m,5H),7.06-6.94(m,2H),6.06(s,1H),5.65(td,J＝15.4,12.4Hz,1H),5.55(s,1H),4.90(t,J＝11.8Hz,1H),3.70-3.44(m,2H),3.29(dd,J＝24.8,11.8Hz,1H),3.04(dd,J＝24.8,11.8Hz,1H),2.54(td,J＝31.2,16.3Hz,1H),2.20(ddt,J＝25.0,16.3,13.0Hz,1H),2.07-1.84(m,3H).ESI-MS m/z 466.18[M+H] +.
实施例88:化合物88的合成
Figure PCTCN2020081481-appb-000108
用化合物11-1替换实施例81中的化合物5-1，合成方法参考化合物81的合成，得到化合物88。
1H NMR(500MHz,Chloroform)δ12.09(s,1H),9.72(s,1H),8.59(dd,J＝7.5,1.5Hz,1H),8.49(s,1H),8.20(dd,J＝7.4,1.3Hz,1H),7.93-7.82(m,2H),7.76(d,J＝7.5Hz,1H),7.57(td,J＝7.5,1.5Hz,1H),7.39-7.26(m,2H),7.00(tdd,J＝5.6,2.9,1.6Hz,2H),6.10(s,1H),5.23(t,J＝7.0Hz,1H),4.55(q,J＝6.5Hz,1H),3.65(dt,J＝12.8,6.5Hz,1H),3.52(dt,J＝12.6,6.5Hz,1H),3.29(dd,J＝12.5,7.0Hz,1H),3.04(dd,J＝12.5,7.0Hz,1H),2.44(tt,J＝9.1,6.1Hz,1H),2.21(ddt,J＝12.8,9.1,6.5Hz,1H),2.02(t,J＝6.4Hz,2H),1.92(ddt,J＝12.7,9.3,6.5Hz,1H).ESI-MS m/z 477.19[M+H] +.
测试例1：2019新型冠状病毒3CL蛋白酶抑制活性评价
测定化合物对2019新型冠状病毒3CL蛋白酶(2019-nCoV 3CL pro)的抑制活性： 利用荧光共振能量转移(fluorescence resonance energy transfer FRET)技术测定针对3C蛋白酶的抑制剂的酶水平抑制活性。在96孔板上，每孔中加入27.5μL缓冲液(20mM Tris，100mM NaCl，1mM EDTA，pH 7.4)，同时加入2.5μL化合物(最终浓度分别为2μM、4μM、6μM、8μM、10μM、12μM、14μM、16μM、18μM、20μM)和5μL EV713Cpro(最终浓度3μM)。在37℃下共孵育15min。之后加入15μL缓冲液稀释的荧光底物(最终浓度20μM)。利用Ge n5荧光分度计测定荧光参数，激发波长和发射波长分别为340nm和490nm，保持37℃，10min后读取数据。采用阴性对照，其中对照不加入化合物，其余相同。所得数据利用软件GraphPad Prism 5处理，实验结果如表1A和1B所示。
表1A:2019新型冠状病毒3CL蛋白酶抑制活性
化合物编号 (1μM)抑制率 化合物编号 (1μM)抑制率
5(DC402265) 95.7 45 85.2
6(DC402264) 95.8 46 89.3
7 88.7 47 90.4
8 86.5 48(DC402234) 100.4
9(DC402240) 95.8 49 91.2
10(DC402237) 88.2 50 89.1
11(DC402238) 89.7 51 84.6
12 103.1 56 81.3
16(DC402267) 89.1(IC 50＝74nM)) 57 92.3
17(DC402266) 105.7 58 94.3
18(DC402306) 97.8 59 86.7
19(DC402308) 98.3 60 92.6
20(DC402310) 100.7 61(DC402207) 88.3
24(DC402307) 93.3 65 86.7
25(DC402309) 101.9 66 68.4
26(DC402311) 101.8 81(DC402259) 96.3
35 94.3 82 100.7
    83 97.8
注：化合物48、或DC402234、或2234(省略了“DC40XXXX”中的“DC40”)指同一个化合物；其他化合物依此类推。
部分优选化合物的IC50值列于表1B。
表1B:抑制2019新型冠状病毒3CL蛋白酶抑制活性(IC 50)
化合物编号 SARS-CoV-2 3CL蛋白酶的IC 50(nM)
5 33.61±3.45
6 48.53±3.17
9 68.14±12.48
10 67.46±13.88
11 178.90±29.39
12 87±8
16 74
17 61.03±12.50
18 238.33±18.67
19 62.73±8.97
20 150.10±9.55
24 131.83±14.73
25 169.23±37.87
26 105.29±10.12
48 53±0.5
81 40±0.2
82 103±13
83 113±9
实验结果显示：多数化合物在1μM的条件下对2019-nCoV 3CL蛋白酶具有较好的抑制活性，一些化合物(化合物48、81、5、6、9、10、12、16、17、19)的IC50小于100nM，其中化合物16(DC402267)对2019-nCoV 3CL蛋白酶的抑制活性IC50达到73.5nM，而化合物48和81的IC50达到53nM和40nM。
测试例2：化合物2019新型冠状病毒复制抑制活性评价和半数毒性浓度测定
2.1 EC 50测定
测定化合物对各2019新型冠状病毒(2019-nCov)复制抑制活性：在96孔中加入100μl/孔梯度浓度的化合物，随后加入50μl/孔病毒缓冲液，随后立即加入50μl/孔培养好后的RD细胞(rhabdomyosarcoma cells)，37℃培养3-4天，直到观察到最大细胞病变效果。吸去培养基，加入75μl 5％MTS的酚红培养基，37℃，5％CO 2培养1.5小时，测定各孔在498nM波长的荧光值，画出化合物浓度与细胞反应的曲线图，用在Accelrys公司定制的软件计算化合物抑制病毒的EC 50。
试验结果如图1和2所示。
结果表明，本发明的醛基类化合物可有效地抑制2019新型冠状病毒的复制(图1)，对不同分离的病毒株有一定的抑制。
目前抗2019-nCoV的阳性化合物为CQ，其抑制2019-nCoV病毒复制的抑制率EC 50＝1.13μM。结果显示：以CQ为阳性对照，在不同的浓度梯度下对专利中的化合物进行测试，化合物2234(DC402234,即化合物48)，2259(DC402259,即化合物81)，2267(DC402267,即化合物16)均具有优良的抑制病毒活性。其中2234的EC 50为0.29μM，2259的EC 50分别为0.33±0.09μM。因此，化合物48和81在病毒水平上对2019-nCoV的抑制率优于阳性对照CQ，展现出较好的抗2019-nCoV潜力(图2)。
2.2半数毒性浓度测定
在本实施例中，通过CCK8试剂盒分析确定部分本发明化合物对Vero E6细胞的半数毒性浓度(CC 50)并且再次测定。
结果如图2所示，化合物16，48和81的CC 50远大于100μM。提示本发明化合物有较高的安全性。
活性实施例3：化合物与SARS-CoV-2 3CL pro形成的晶体复合物
3.1 SARS-CoV-2 3CL pro(M pro)的克隆、表达、纯化和结晶
对编码SARS-CoV-2 3CL pro的全长基因进行了优化和合成，并将其插入到pGEX-6p-1质粒DNA(Amersham Biosciences)的BamHI和XhoI位点，用于大肠杆菌(E.coil)表达(GENEWIZ)。SARS-CoV-2 3CL pro经进一步纯化后进行共晶。SARS-CoV-2 3CL pro与10mM化合物48或化合物81孵育30min，悬垂液滴蒸汽扩散法在20℃下结晶(5mg/ml)。用含2％聚乙二醇(PEG)6000、3％DMSO、1mM DTT、0.1M MES(pH 6.0)的缓冲液生长出最佳晶体。低温保护剂溶液中含有30％PEG 400,0.1M MES(pH 6.0)。
3.2晶体复合物数据收集和细化统计
所有数据采集于上海同步辐射设备(SSRF)的光束线BL19U1上，使用Pilatus3 6M图像板检测器，采集波长为
Figure PCTCN2020081481-appb-000109
温度为100K。使用XDS25程序进行数据集成和扩展。用SARS-CoV 3CL pro(PDB:2H2Z)作为搜索模型，使用PHASER26程序进行分子替换(MR)，确定结构。MR的输出模型随后用Coot27进行手动调整模型的迭代循环，用Phenix进行细化。化合物48和81是根据略图构建的。
3.3结果
结果如表2和图3所示。
表2：晶体复合物数据收集和细化统计
Figure PCTCN2020081481-appb-000110
a括号内的数值是这对于最高分辨率的结构。
SARS-CoV-2 3CL pro与化合物48以及81的坐标和结构因子等数据已分别存入蛋白数据库，PDB号分别为6LZE和6M0K。
化合物48、81与SARS-CoV-2 3CL pro晶体复合物的结构如图3所示。
实验结果显示：化合物48的醛基C与SARS-CoV-2 M pro的催化位点Cys145形成标准的
Figure PCTCN2020081481-appb-000111
C-S共价键(图3B)，显示发生Michael加成反应。此外，醛基的氧原子通过与S1口袋的Cys145残基和Gly143残基形成氢键，对稳定化合物的构象也起着至关重要的作用(图3B)。五元环内酰胺能顺利的插入到S1口袋(图3B)。内 酰胺的氧原子与侧链的His163残基形成氢键。Phe140的主链和侧链Glu166通过与NH形成氢键也参与稳定五元环内酰胺。此外，化合物48主链上的酰胺键分别与His164和Glu166的主链成氢键(图3B)。化合物48的环己基深入S2口袋，被Met49、Tyr54、Met165和Asp187的侧链包围，产生广泛的疏水相互作用(图3B)。化合物48的吲哚基团暴露于溶剂中(S4口袋)，通过氢键被Glu166稳定(图3B)。Pro168和Gln189残基的侧链通过疏水相互作用与化合物48的吲哚基团相互作用。并且，多个水分子(命名为W1-W6)在结合化合物48中起着重要作用(图3B)。W1通过氢键与化合物48的酰胺键相互作用，而W2-6与化合物48的醛基和Asn142、Gly143、Thr26、Thr25、His41、Cys44的残基形成多个氢键，有助于稳定结合袋中的化合物48(图3B)。
化合物81与SARS-CoV-2 M pro的晶体结构与化合物48非常相似，表现出类似的抑制剂结合模式(图3C、3D)。而结合的差异可能是由化合物81的芳基造成的。与化合物48中的环己基相比，化合物81的芳基发生了显著的旋转(图3C)。His41、Met49、Met165和Val186残基的侧链通过疏水相互作用与芳基相互作用(图3D)。Gln189的侧链通过与氟原子形成一个额外的氢键来稳定芳基(图3D)。
简而言之，这两种晶体结构揭示了一种相同的抑制机制，即这两种化合物占据底物结合口袋，模仿催化反应中的中间体，阻断了SARS-CoV-2 M pro的酶活性。
在本发明提及的所有文献都在本申请中引用作为参考，就如同每一篇文献被单独引用作为参考那样。此外应理解，在阅读了本发明的上述讲授内容之后，本领域技术人员可以对本发明作各种改动或修改，这些等价形式同样落于本申请所附权利要求书所限定的范围。

Claims (15)

  1. 一种通式(I)所示的醛基类化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体的用途，其特征在于，用于制备(a)2019新型冠状病毒(2019-nCov)3CL蛋白酶抑制剂；和(b)治疗和/或预防、缓解由2019新型冠状病毒(2019-nCov)感染引起的相关疾病的药物：
    Figure PCTCN2020081481-appb-100001
    其中，
    手性碳原子C*、C* 2、C* 3、C* 4各自独立地为S型、R型，或其组合；
    n＝0或1；
    R 1选自未被取代或者被1-3个取代基取代的以下基团：C3～C7环烷基、三氟甲基、C2～C6炔基、4～7元杂环基、C5～C7芳基、5～7元杂芳基；所述杂环基和杂芳基各自含有1～3个选自氧、硫和氮的杂原子；所述的取代基各自独立地选自下组：卤素、C1～C4直链或支链烷基、C1～C4直链或支链烯基、C2～C4直链或支链炔基、C1～C4直链或支链烷氧基、C1～C4直链或支链烷基羰氧基、氰基、硝基、羟基、氨基、羟甲基、三氟甲基、羧基、巯基、C1-C4酰基、酰胺基、磺酰基、氨基磺酰基、C1-C4烷基取代的磺酰基，或者两个相邻的取代基连同与其连接的碳原子构成5-7元环；
    R 2选自未被取代或者被1-3个取代基取代的以下基团：C3～C7环烷基、5～12元杂环基(优选为5～7元杂环基或6元芳基并5～7元杂环基)、C6～C12芳基、5～12元杂芳基、苯乙烯基、或-Cbz；其中，各个所述杂环基或杂芳基含有1～3个选自氧、硫和氮的杂原子；所述的取代基各自独立地选自卤素、C1～C6直链或支链烷基、C2～C6直链或支链烯基、C2～C6直链或支链炔基、C1～C6直链或支链烷氧基、C1～C6直链或支链烷基羰氧基、氰基、硝基、羟基、氨基、羟甲基、三氟甲基、羧基、巯基、C1-C4酰基、酰胺基、磺酰基、氨基磺酰基、C1-C4烷基取代的磺酰基，或者两个相邻的取代基连同与其连接的碳原子构成5-7元环；
    R 3选自未被取代或者被1-3个取代基取代的以下基团：C1～C6直链或支链烷基、C1～C6直链或支链烷氧基、C3～C7环烷基、C6～C12芳基、5～12元杂芳基，其中所述杂芳基含有1～3个选自氧、硫和氮的杂原子；其中，所述的取代基各自独立地选自卤素、C1～C6直链或支链烷基、C2～C6直链或支链烯基、C2～C6直链或支链炔基、C1～C6直链或支链烷氧基、C1～C6直链或支链烷基羰氧基、氰基、硝基、 羟基、氨基、羟甲基、三氟甲基、羧基、巯基、C1-C4酰基、酰胺基、磺酰基、氨基磺酰基、C1-C4烷基取代的磺酰基，或者两个相邻的取代基连同与其连接的碳原子构成5-7元环。
  2. 如权利要求1所述的用途，其特征在于，所述由2019新型冠状病毒感染引起的相关疾病选自下组：呼吸道感染、肺炎及其并发症、或其组合。
  3. 如权利要求1或2所述的用途，其特征在于，R 1选自未被取代或者被1-3个取代基取代的以下基团：三氟甲基、炔基、环丙烷基、环丁烷基、环戊烷基、环己烷基、苯基、噻吩基、吡唑基、噻唑基、吡啶基、呋喃基。
  4. 如权利要求1或2所述的用途，其特征在于，R 1选自未被取代或者被1-3个取代基取代的以下基团：三氟甲基、炔基、环丙烷基、环丁烷基、环戊烷基、环己烷基、苯基、噻吩基、吡唑基、噻唑基、吡啶基、呋喃基；和/或
    R 2为未被取代或者被1-3个取代基取代的选自下组的基团：苯基、苯乙烯基、苯并杂环基、5～12元杂芳基；优选地，所述苯并杂环和5～12元杂芳环选自苯并二氧杂环戊烯、吲哚、异噁唑、2-氢丙吡喃、吡啶、吡唑、二氢咪唑并吡啶、咪唑并吡啶、苯并噻吩、二氢苯并二氧六环、喹喔林、苯并呋喃、吲唑、苯并咪唑、喹啉。
  5. 如权利要求1或2所述的用途，其特征在于，手性碳原子C*、C* 2、C* 3、C* 4为S型；和/或
    R 1选自未被取代或者被1-3个取代基取代的以下基团：三氟甲基、炔基、环丙烷基、环丁烷基、环戊烷基、环己烷基、苯基、噻吩基、吡唑基、噻唑基、吡啶基、呋喃基；和/或
    R 2为未被取代或者被1-3个取代基取代的选自下组的基团：苯基、苯乙烯基、苯并杂环基、5～12元杂芳基；优选地，所述苯并杂环和5～12元杂芳环选自苯并二氧杂环戊烯、吲哚、异噁唑、2-氢丙吡喃、吡啶、吡唑、二氢咪唑并吡啶、咪唑并吡啶、苯并噻吩、二氢苯并二氧六环、喹喔林、苯并呋喃、吲唑、苯并咪唑、喹啉；和/或
    R 3选自未被取代或者被1-3个取代基取代的以下基团：C1～C6直链或支链烷基、C3～C7环烷基、苯基。
  6. 如权利要求1或2所述的用途，其特征在于，所示通式(I)中化合物选自下组：
    Figure PCTCN2020081481-appb-100002
    Figure PCTCN2020081481-appb-100003
    Figure PCTCN2020081481-appb-100004
    Figure PCTCN2020081481-appb-100005
    Figure PCTCN2020081481-appb-100006
    Figure PCTCN2020081481-appb-100007
    Figure PCTCN2020081481-appb-100008
    Figure PCTCN2020081481-appb-100009
    Figure PCTCN2020081481-appb-100010
    Figure PCTCN2020081481-appb-100011
    Figure PCTCN2020081481-appb-100012
    Figure PCTCN2020081481-appb-100013
    Figure PCTCN2020081481-appb-100014
    Figure PCTCN2020081481-appb-100015
    Figure PCTCN2020081481-appb-100016
  7. 一种药物组合物，其特征在于，所述的药物组合物含有(a)通式(I)所示的醛基类化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体；以及(b)药学上可接受的载体，
    Figure PCTCN2020081481-appb-100017
    其中，
    手性碳原子C*、C* 2、C* 3、C* 4各自独立地为S型、R型，或其组合；
    n＝0或1；
    R 1选自未被取代或者被1-3个取代基取代的以下基团：C3～C7环烷基、三氟甲基、C2～C6炔基、4～7元杂环基、C5～C7芳基、5～7元杂芳基；所述杂环基和杂芳基各自含有1～3个选自氧、硫和氮的杂原子；所述的取代基各自独立地选自下组：卤素、C1～C4直链或支链烷基、C1～C4直链或支链烯基、C2～C4直链或支链炔基、C1～C4直链或支链烷氧基、C1～C4直链或支链烷基羰氧基、氰基、硝基、羟基、氨基、羟甲基、三氟甲基、羧基、巯基、C1-C4酰基、酰胺基、磺酰基、氨基磺酰基、C1-C4烷基取代的磺酰基，或者两个相邻的取代基连同与其连接的碳原子构成5-7元环；
    R 2选自未被取代或者被1-3个取代基取代的以下基团：C3～C7环烷基、5～12元杂环基(优选为5～7元杂环基或6元芳基并5～7元杂环基)、C6～C12芳基、5～12元杂芳基、苯乙烯基、或-Cbz；其中，各个所述杂环基或杂芳基含有1～3个选自氧、硫和氮的杂原子；所述的取代基各自独立地选自卤素、C1～C6直链或支链烷基、C2～C6直链或支链烯基、C2～C6直链或支链炔基、C1～C6直链或支链烷氧基、C1～C6直链或支链烷基羰氧基、氰基、硝基、羟基、氨基、羟甲基、三氟甲基、羧基、巯基、C1-C4酰基、酰胺基、磺酰基、氨基磺酰基、C1-C4烷基取代的磺酰基，或者两个相邻的取代基连同与其连接的碳原子构成5-7元环；
    R 3选自未被取代或者被1-3个取代基取代的以下基团：C1～C6直链或支链烷基、 C1～C6直链或支链烷氧基、C3～C7环烷基、C6～C12芳基、5～12元杂芳基，其中所述杂芳基含有1～3个选自氧、硫和氮的杂原子；其中，所述的取代基各自独立地选自卤素、C1～C6直链或支链烷基、C2～C6直链或支链烯基、C2～C6直链或支链炔基、C1～C6直链或支链烷氧基、C1～C6直链或支链烷基羰氧基、氰基、硝基、羟基、氨基、羟甲基、三氟甲基、羧基、巯基、C1-C4酰基、酰胺基、磺酰基、氨基磺酰基、C1-C4烷基取代的磺酰基，或者两个相邻的取代基连同与其连接的碳原子构成5-7元环。
  8. 如权利要求7所述的药物组合物的用途，其特征在于，用于制备治疗和/或预防、缓解由2019新型冠状病毒(2019-nCov)感染引起的相关疾病的药物。
  9. 如权利要求8所述的用途，其特征在于，所述由2019新型冠状病毒感染引起的相关疾病选自下组：呼吸道感染、肺炎及其并发症、或其组合。
  10. 一种通式(I)所示的醛基类化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体；
    Figure PCTCN2020081481-appb-100018
    其中，
    手性碳原子C*、C* 2、C* 3、C* 4各自独立地为S型、R型，或其组合；
    n＝0或1；
    R 1选自未被取代或者被1-3个取代基取代的以下基团：C3～C7环烷基、三氟甲基、C2～C6炔基、4～7元杂环基、C5～C7芳基、5～7元杂芳基；所述杂环基和杂芳基各自含有1～3个选自氧、硫和氮的杂原子；所述的取代基各自独立地选自下组：卤素、C1～C4直链或支链烷基、C1～C4直链或支链烯基、C2～C4直链或支链炔基、C1～C4直链或支链烷氧基、C1～C4直链或支链烷基羰氧基、氰基、硝基、羟基、氨基、羟甲基、三氟甲基、羧基、巯基、C1-C4酰基、酰胺基、磺酰基、氨基磺酰基、C1-C4烷基取代的磺酰基，或者两个相邻的取代基连同与其连接的碳原子构成5-7元环；
    R 2选自未被取代或者被1-3个取代基取代的以下基团：C3～C7环烷基、5～12元杂环基(优选为5～7元杂环基或6元芳基并5～7元杂环基)、C6～C12芳基、5～12元杂芳基、苯乙烯基、或-Cbz；其中，各个所述杂环基或杂芳基含有1～3个选自氧、硫和氮的杂原子；所述的取代基各自独立地选自卤素、C1～C6直链或支链烷基、C2～C6直链或支链烯基、C2～C6直链或支链炔基、C1～C6直链或支链烷氧基、C1～C6直链或支链烷基羰氧基、氰基、硝基、羟基、氨基、羟甲基、三氟甲基、羧 基、巯基、C1-C4酰基、酰胺基、磺酰基、氨基磺酰基、C1-C4烷基取代的磺酰基，或者两个相邻的取代基连同与其连接的碳原子构成5-7元环；
    R 3选自未被取代或者被1-3个取代基取代的以下基团：C1～C6直链或支链烷基、C1～C6直链或支链烷氧基、C3～C7环烷基、C6～C12芳基、5～12元杂芳基，其中所述杂芳基含有1～3个选自氧、硫和氮的杂原子；其中，所述的取代基各自独立地选自卤素、C1～C6直链或支链烷基、C2～C6直链或支链烯基、C2～C6直链或支链炔基、C1～C6直链或支链烷氧基、C1～C6直链或支链烷基羰氧基、氰基、硝基、羟基、氨基、羟甲基、三氟甲基、羧基、巯基、C1-C4酰基、酰胺基、磺酰基、氨基磺酰基、C1-C4烷基取代的磺酰基，或者两个相邻的取代基连同与其连接的碳原子构成5-7元环。
  11. 如权利要求10所述的化合物，其特征在于，R 1选自未被取代或者被1-3个取代基取代的以下基团：三氟甲基、炔基、环丙烷基、环丁烷基、环戊烷基、环己烷基、苯基、噻吩基、吡唑基、噻唑基、吡啶基、呋喃基。
  12. 如权利要求10所述的化合物，其特征在于，R 1选自未被取代或者被1-3个取代基取代的以下基团：三氟甲基、炔基、环丙烷基、环丁烷基、环戊烷基、环己烷基、苯基、噻吩基、吡唑基、噻唑基、吡啶基、呋喃基；和/或
    R 2为未被取代或者被1-3个取代基取代的选自下组的基团：苯基、苯乙烯基、苯并杂环基、5～12元杂芳基；优选地，所述苯并杂环和5～12元杂芳环选自苯并二氧杂环戊烯、吲哚、异噁唑、2-氢丙吡喃、吡啶、吡唑、二氢咪唑并吡啶、咪唑并吡啶、苯并噻吩、二氢苯并二氧六环、喹喔林、苯并呋喃、吲唑、苯并咪唑、喹啉。
  13. 如权利要求10所述的化合物，其特征在于，手性碳原子C*、C* 2、C* 3、C* 4为S型；和/或
    R 1选自未被取代或者被1-3个取代基取代的以下基团：三氟甲基、炔基、环丙烷基、环丁烷基、环戊烷基、环己烷基、苯基、噻吩基、吡唑基、噻唑基、吡啶基、呋喃基；和/或
    R 2为未被取代或者被1-3个取代基取代的选自下组的基团：苯基、苯乙烯基、苯并杂环基、5～12元杂芳基；优选地，所述苯并杂环和5～12元杂芳环选自苯并二氧杂环戊烯、吲哚、异噁唑、2-氢丙吡喃、吡啶、吡唑、二氢咪唑并吡啶、咪唑并吡啶、苯并噻吩、二氢苯并二氧六环、喹喔林、苯并呋喃、吲唑、苯并咪唑、喹啉；和/或
    R 3选自未被取代或者被1-3个取代基取代的以下基团：C1～C6直链或支链烷基、C3～C7环烷基、苯基。
  14. 如权利要求10所述的化合物，其特征在于，所述通式(I)中化合物为表A中的化合物1～88。
  15. 一种治疗、预防、和/或缓解由2019新型冠状病毒(2019-nCov)感染引起 的相关疾病的方法，其特征在于，包括步骤：给需要的对象施用安全有效量的通式(I)所示的醛基类化合物、或其药学上可接受的盐、对映异构体、非对映异构体或外消旋体，其中所述的通式(I)所示的醛基类化合物如权利要求10中所述。
PCT/CN2020/081481 2020-01-29 2020-03-26 一种醛基类化合物的药物用途 WO2021151265A1 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202080095393.2A CN115087653B (zh) 2020-01-29 2020-03-26 一种醛基类化合物的药物用途
EP20916984.6A EP4098653A1 (en) 2020-01-29 2020-03-26 Pharmaceutical use of aldehyde-based compound
US17/759,807 US20230138310A1 (en) 2020-01-29 2020-03-26 Pharmaceutical use of aldehyde-based compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010077463.3 2020-01-29
CN202010077463.3A CN113181339B (zh) 2020-01-29 2020-01-29 一种醛基类化合物的药物用途

Publications (1)

Publication Number Publication Date
WO2021151265A1 true WO2021151265A1 (zh) 2021-08-05

Family

ID=76972529

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/081481 WO2021151265A1 (zh) 2020-01-29 2020-03-26 一种醛基类化合物的药物用途

Country Status (4)

Country Link
US (1) US20230138310A1 (zh)
EP (1) EP4098653A1 (zh)
CN (2) CN113181339B (zh)
WO (1) WO2021151265A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds
US11952365B2 (en) 2020-06-10 2024-04-09 Aligos Therapeutics, Inc. Anti-viral compounds

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113181339B (zh) * 2020-01-29 2022-02-22 中国科学院上海药物研究所 一种醛基类化合物的药物用途
WO2022268111A1 (zh) * 2021-06-25 2022-12-29 前沿生物药业(南京)股份有限公司 抗病毒药物组合物及其制备方法和应用
CA3230035A1 (en) * 2021-09-30 2023-04-06 Xiangrui Jiang Cyano compounds, and preparation method therefor and use thereof
WO2023136277A1 (ja) * 2022-01-12 2023-07-20 株式会社Preferred Networks 化合物及びその使用
CN114957383A (zh) * 2022-04-01 2022-08-30 中国科学院上海药物研究所 一种拟肽类化合物及其制备方法、药物组合物和用途
WO2023198067A1 (zh) * 2022-04-11 2023-10-19 上海科技大学 一种化合物及其在制备治疗肠道病毒相关疾病的药物中的应用
CN115466225A (zh) * 2022-08-16 2022-12-13 中国科学院上海药物研究所 一种酰胺类化合物及其制备方法、药物组合物和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102838523A (zh) * 2011-06-23 2012-12-26 南开大学 抗肠病毒71(ev71)戊内酰胺类化合物及其制备方法和用途
WO2013049382A2 (en) * 2011-09-27 2013-04-04 Kansas State University Research Foundation Broad-spectrum antivirals against 3c or 3c-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses
CN106928206A (zh) * 2015-12-31 2017-07-07 中国科学院上海药物研究所 醛基类化合物及其制法和用途
CN110818691A (zh) * 2018-08-09 2020-02-21 中国科学院上海药物研究所 酮酰胺类化合物及其制备方法、药物组合物和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2844249A4 (en) * 2012-05-02 2016-03-09 Univ Kansas State MACROCYCLIC AND PEPTIDOMIMETIC COMPOUNDS AS VIRUZIDES AGAINST 3C OR 3C LIKE PROTEASES OF PICORNIVERS, CALICIVIRES AND CORONA VIRUSES
CN113181339B (zh) * 2020-01-29 2022-02-22 中国科学院上海药物研究所 一种醛基类化合物的药物用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102838523A (zh) * 2011-06-23 2012-12-26 南开大学 抗肠病毒71(ev71)戊内酰胺类化合物及其制备方法和用途
WO2013049382A2 (en) * 2011-09-27 2013-04-04 Kansas State University Research Foundation Broad-spectrum antivirals against 3c or 3c-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses
CN106928206A (zh) * 2015-12-31 2017-07-07 中国科学院上海药物研究所 醛基类化合物及其制法和用途
CN110818691A (zh) * 2018-08-09 2020-02-21 中国科学院上海药物研究所 酮酰胺类化合物及其制备方法、药物组合物和用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KUMAR VATHAN; SHIN JIN SOO; SHIE JIUN-JIE; KU KEUN BON; KIM CHONSAENG; GO YUN YOUNG; HUANG KAI-FA; KIM MEEHYEIN; LIANG PO-HUANG: "Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLProinhibitors", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 141, 17 February 2017 (2017-02-17), NL, pages 101 - 106, XP029949617, ISSN: 0166-3542, DOI: 10.1016/j.antiviral.2017.02.007 *
KUO, C.J. ; SHIE, J.J. ; FANG, J.M. ; YEN, G.R. ; HSU, J.T.A. ; LIU, H.G. ; TSENG, S.N. ; CHANG, S.C. ; LEE, C.Y. ; SHIH, S.R. ; L: "Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 16, no. 15, 1 August 2008 (2008-08-01), AMSTERDAM, NL, pages 7388 - 7398, XP023610717, ISSN: 0968-0896, DOI: 10.1016/j.bmc.2008.06.015 *
NIE QUANDENG, XU XIAOYI, ZHANG QI, MA YUYING, YIN ZHENG, SHANG LUQING: "3D-quantitative structure-activity relationship study for the design of novel enterovirus A71 3C protease inhibitors", CHEMICAL BIOLOGY & DRUG DESIGN, BLACKWELL MUNKSGAARD, vol. 92, no. 4, 1 October 2018 (2018-10-01), pages 1750 - 1762, XP055832524, ISSN: 1747-0277, DOI: 10.1111/cbdd.13344 *
ZHANG LINLIN, LIN DAIZONG, KUSOV YURI, NIAN YONG, MA QINGJUN, WANG JIANG, VON BRUNN ALBRECHT, LEYSSEN PIETER, LANKO KRISTINA, NEYT: "α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 63, no. 9, 11 February 2020 (2020-02-11), pages 4562 - 4578, XP055806728, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.9b01828 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11952365B2 (en) 2020-06-10 2024-04-09 Aligos Therapeutics, Inc. Anti-viral compounds
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds

Also Published As

Publication number Publication date
CN115087653A (zh) 2022-09-20
CN113181339A (zh) 2021-07-30
US20230138310A1 (en) 2023-05-04
CN113181339B (zh) 2022-02-22
EP4098653A1 (en) 2022-12-07
CN115087653B (zh) 2023-11-17

Similar Documents

Publication Publication Date Title
WO2021151265A1 (zh) 一种醛基类化合物的药物用途
ES2544532T3 (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
WO2017114509A1 (zh) 醛基类化合物及其制法和用途
CN113620929B (zh) 醛基类化合物及其制备方法、药物组合物和用途
JP6026400B2 (ja) （１ｓ，２ｓ，３ｓ，４ｒ）−３−［（１ｓ）−１−アセチルアミノ−２−エチル−ブチル］−４−グアニジノ−２−ヒドロキシ−シクロペンチル−１−カルボン酸水和物の製造方法
BR112012030010A2 (pt) 5-flúor-1h-pirazolopiridinas substituídas e seu uso
SK8712000A3 (en) Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
EA010804B1 (ru) ПРОИЗВОДНЫЕ БОРОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ ПРОТЕАСОМ, СПОСОБЫ ИНГИБИРОВАНИЯ АКТИВНОСТИ ПРОТЕАСОМЫ, ФАКТОРА ТРАНСКРИПЦИИ NF-kB И ДЕГРАДАЦИИ БЕЛКА И СПОСОБ ЛЕЧЕНИЯ РАКА
CN111803501B (zh) 手性氯喹羟氯喹作为降低心脏毒性的用途
CN111410661A (zh) 帽依赖性内切核酸酶抑制剂及其用途
CN110105348A (zh) 新型迈克尔受体类肠病毒71型抑制剂的制备及用途
WO2024037520A1 (zh) 一种酰胺类化合物及其制备方法、药物组合物和用途
CN112771048B (zh) 流感病毒复制抑制剂及其中间体和用途
WO2023125846A1 (zh) 用于预防和治疗冠状病毒感染的化合物及其偶联物和方法
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
WO2019149734A1 (en) Cycloalkyl substituted pyrazolopyrimidines having activity against rsv
TW200521126A (en) Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders
WO2023185763A1 (zh) 一种拟肽类化合物及其制备方法、药物组合物和用途
CN110950856B (zh) 8-(苯并呋喃-5-基)苯并噁嗪二酮及其作为抗癌药物的应用
CN103814025A (zh) 可用作胆碱激酶抑制剂的化合物
CA2968090A1 (en) 4h-pyrido[1,2-a]pyrimidin-4-one compounds
CA3176618A1 (en) Antiviral 1,3-di-oxo-indene compounds
CN105130995B (zh) 吡咯酮类化合物及其制备方法和应用
WO2021047688A1 (zh) 硝唑尼特衍生物及其医药用途
WO2021188620A1 (en) Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20916984

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020916984

Country of ref document: EP

Effective date: 20220829